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A whole cell-based screen of natural product for new anti-TB agents at Novartis identified a 
Compound X displaying potent activity against M. tuberculosis. This compound is active against 
multidrug resistant clinical isolates, implying a new target. In a pull-down experiment with 
immobilized Compound X and BCG lysate, ClpC1 was identified as the potential target (Schmitt 
E. et al. unpublished data). The ClpC form of Clp/HSP100 family is an essential, highly 
conserved protein that interacts with ClpP peptidase to degrade specific substrates, and yet little is 
known regarding its specific activity as a molecular chaperone in M. tuberculosis. To address this 
and to confirm the target of Compound X, ClpC1 from M. tuberculosis was purified using an E. 
coli-based overexpression system. We have found that recombinant ClpC1 display basal ATPase 
activity, similar to that of other types of HSP100 proteins but without the need of other 
chaperones or adaptor proteins. Most significantly, we demonstrate that ClpC1 basal ATPase 
activity was enhanced in the presence of Compound X and was specific to this ATPase. 
Consistent with this observation, we show that only structural derivatives of Compounds X with 
potent whole cell activity had stimulating ClpC1 ATPase activity. Of further interest is the 
finding that binding of Compounds X to ClpC1 also resulted in enhanced proteolytic efficiency of 
ClpC1P complex. Such activation leads to inhibition of bacterial growth and suggest that ClpC1 
is involved in key processes of importance for the multiplication of M. tuberculosis. 
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Tuberculosis (TB) is not a disease of the past. It remains a major cause of illness and death 
worldwide, especially in Asia and Africa (Figure 1.1). Globally, there were an estimated 9.2 
million new TB cases with 1.7 million deaths and 4.1 million new smear-positive cases in 2006, 
including 0.7 million cases and 0.2 million deaths in HIV-positive people (WHO, 2008). The 
disease itself is caused by Mycobacterium tuberculosis, bacteria that are spread in airborne 
droplets when people with active tuberculosis sneeze or cough.  
 
Infections with M. tuberculosis can result in latent or sometimes, active tuberculosis. Clinically, 
the infection can be controlled entirely by the innate immune system and the infected individuals 
remain asymptomatic (Grosset, 2003). However, it can also progress to a latent state with a 10% 
lifetime chance of reactivation to the active disease (Gedde-Dahl, 1952; Grosset, 2003). In latent 
tuberculosis, patients are asymptomatic but positive for the purified protein derivative (PPD) test, 
a diagnosis for the disease. The World Health Organization currently estimates that two billion 
people are latently infected with M. tuberculosis, with the vast majority showing no symptoms or 
disease (Dye et al., 1999). It remains uncertain if M. tuberculosis enters a dormant state, or that a 
fine balance between replication of the bacilli and its elimination by the host immune system is 
achieved (Cosma et al., 2003; Parrish et al., 1998). 
 
HIV infection can greatly alter the natural progression of TB disease, and vice versa. Individuals 
with latent M. tuberculosis infection who contract HIV are at risk of developing active TB at a 
rate of 7-10% per year, in contrast to approximately 8% per lifetime for HIV-negative individuals 
(Selwyn et al., 1989; Selwyn et al., 1992)). HIV-infected persons recently infected with M. 
tuberculosis may progress to active disease at a rate over 35% within the first 6 months, 
compared to 2-5% in the first 2 years among HIV-negative individuals (Daley et al., 1992). 
Introduction 
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Patients with advanced HIV-induced CD4+ T-cell depletion are more susceptible to TB where 
CD4+ T-cells seem to play a protective role. Meanwhile, the host immune response to M. 
tuberculosis can enhance HIV replication and accelerate the natural course of HIV/ADIS (Toossi 
et al., 1993). This is mainly because M. tuberculosis infection results in macrophage activation, 
which can house resident HIV virions, resulting in active expression of HIV antigens rather than 
the prolonged latencywithout antigenic expression of HIV proteins (Toossi et al., 1993). In 
support of this, Pape et al. observed more rapid progression to AIDS among tuberculin skin test 
positive individuals not given treatment for latent TB infection (INH) than among those who were 
treated with INH (Pape et al., 1993). Thus, HIV infection tends to accelerate the progression of 
TB, while in turn, the host immune response to M. tuberculosis can enhance HIV replication and 
may accelerate the natural course of HIV/AIDS. 
 
The current gold standard for diagnosis of active tuberculosis is to microscopically determine the 
presence of acid-fast bacilli in patient’s sputum samples following isolation of M. tuberculosis in 
culture (Merck, 2005; Nahid et al., 2006). Other diagnostic methods include chest X-ray, 
tuberculin skin test and IFNγ-based assays. Previously, the tuberculin or Mantoux test, where 
purified protein derivative (PPD) of M. tuberculosis is injected intradermally, was the only 
method available for diagnosis of latent tuberculosis. However, these results can be confounded 
by prior BCG vaccination and exposure to non-tuberculous environmental bacteria (Nahid et al., 
2006; Pai, 2005). To circumvent this problem, an IFNγ-based assay was developed using RD1 
antigens such as namely 6-kDa early secreted antigenic target (ESAT-6) and 10-kDa 
culture filtrate protein (CFP-10) (Dheda et al., 2005; Lalvani, 2003; Nahid et al., 2006; Pai, 
2005; Pai et al., 2004). Studies have shown that this tests is more specific, especially in 
patients who have received BCG vaccination, and are proven to be more sensitive than 
the Mantoux test (Nahid et al., 2006; Pai, 2005). The QuantiFERON-TB Gold test is based 
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on the quantification of interferon-gamma (IFN-γ) released from sensitized lymphocytes in whole 
blood incubated overnight with purified protein derivative (PPD) from M. tuberculosis and 
control antigens. In a similar concept, T-SPOT TB test counts the number of effector T cells, 
white blood cells that produce gamma interferon in a sample of blood, thus giving an overall 
measurement of the antigen load on the immune system. Another diagnostic test, called Amplicor 
MTB test, which uses polymerase chain reaction (PCR) to detect M. tuberculosis has also been 
developed (Roche Diagnostic Systems, United States) (Nahid et al., 2006). 
 
The bacilli Calmette-Guerin (BCG) vaccine is currently the only vaccine available for protection 
against TB. It was developed from attenuated Mycobacterium bovis that had been passaged 
several hundred times leading to several gene deletions. The protection conferred by this vaccine, 
however, is variable, possibly due to exposure to Mycobacterium tuberculosis-like antigens 
derived from environmental mycobacteria (Brandt et al., 2002; Fine, 1995).  
 
 
Figure 1.1 Estimated TB incidence rates, by country, 2006 (WHO Report 2008). The magnitude of TB 




The current treatment against TB approved by WHO is a multi-drug therapy comprising two 
months treatment with rifampicin, isoniazid, pyrazinamide and ethambutol (intensive phase) 
followed by four months treatment with rifampicin and isoniazid (continuation phase) (WHO, 
2003). Treatment is effective and leads to complete sterilization if compliance has been observed 
and if the infecting TB strain is not drug-resistant. Sometimes, persistence occurs when the 
causative organism, M. tuberculosis, survives despite the use of antibiotics. Persistence leads to 
extended drug treatment and long courses of antibiotics to cure patients and prevent relapse. 
Coupled with the complicated therapy regimen, the long course of treatment often results in 
patient non-compliance. Patient either takes incorrect combination of drugs or does not complete 
the full therapy.  
 
The incidence of multi-drug resistance TB (MDR-TB) whereby the bacilli are resistant to at least 
isoniazid and rifampicin, can be documented in every country surveyed by WHO. Lack of 
compliance is generally the main cause of TB drug-resistant. Despite being treatable, drug-
resistant TB requires extensive chemotherapy with second line anti-TB drugs which are more 
costly and produce more severe adverse drug reactions than the first-line treatments. TB drug 
resistance can be traced to genetic mutations that result in heritable loss of susceptibility to 
antibiotics. Such mutations can occur in the target or the activator of the drug. For the summary 
of the most common mutations in the first and second line drugs, refer to Table 1.1 The 
emergence of extensively drug-resistant TB (XDR-TB), in which the bacilli are resistant to 
isoniazid, rifampin, any fluoroquinolone and at least one of three injectable second-line drugs 
(i.e., amikacin, kanamycin, or capreomycin), poses a serious threat to TB control. Patients are left 
with treatment options that are much less effective. Thus, there is a great demand for new drugs 




The Global Alliance for TB Drug Development (http://www.tballiance.org) recommends that an 
ideal new TB drug should shorten the duration of effective therapy, improve the treatment of 
MDR-TB and in light of the fact that two billion people are latently infected with Mycobacterium 
tuberculosis, the drugs need to have efficacy against latent tuberculosis (Duncan, 2004; O'Brien 
and Nunn, 2001; O'Brien and Spigelman, 2005). Sacchettini et al (2008) provided a 
comprehensive review on the recent and ongoing efforts to produce new antitubercular drugs.  
 
Table 1.1 Mechanisms of actions and resistance of current first-line (LEFT) and second-line (RIGHT) 









Nevertheless, since the 1960s, there has been little progress in available therapies. Anti-TB agents 
that are currently available are complicated by compliance due to long duration of therapy and 
not to mention the various side-effects and drug interactions. To add on to the list is the emerging 
drug resistance that further complicates the disease management. The urgent need for new anti-
TB drugs drives the search for novel drug targets in TB. One of the novel targets currently on the 
rise is the bacterial protease. The link between bacterial protease and pathogenesis has been 
established by various studies and the results suggest that they are potential good targets for the 
development of novel antimicrobial therapy. In the next section of this introduction we 
summarize a handful of these studies, not necessarily confined to the antimycobacterial research. 
We aim to highlight the importance of bacterial protease as potential drug target and extrapolate 
the results of previous studies in other bacteria to our need in antituberculous research. 
 
1.2 Overview of ATP-dependent protease 
Bacterial protease has been implicated in the regulation of intracellular protein level in order to 
adapt to changes in both external and internal conditions. This is often achieved via specific 
degradation involving proteases. Proteases play a vital role in protein quality control by removing 
short-lived regulatory proteins, misfolded and damaged proteins that arise from slow rates folding 
or assembly, chemical or thermal stress, intrinsic structural instability, and biosynthetic errors. 
Proteolytic removal of these dysfunctional and thus potentially toxic polypeptides is crucial in the 
maintenance of cellular homeostasis and optimal metabolic activities. 
 
Evidence has shown that the process of protein degradation in both prokaryotic and eukaryotic is 
energy-dependent; and inhibition of ATP production in vivo dramatically inhibits protein 
degradation (Maurizi, 1992). Different families of ATP-dependent proteases have been 
characterized in bacteria: Clp, HslUV, FtsH, Lon and Proteasome family. All of these proteases 
Introduction 
 8 
share a number of common features. First, access to the active sites of proteolysis is prohibited to 
globular proteins by a constricted pore entrance to the protease chamber; thus, the protease is 
‘self-compartmentalized’. It is presumed that this inaccessibility prevents rampant protein 
degradation by these proteases. As a result of this structure, proteins must first be unfolded and 
threaded into the protease chamber for degradation. Thus, the second common feature of these 
proteases is the requirement of ATP hydrolysis, usually by ATPases of the AAA or AAA+ 
superfamily (ATPases associated with various cellular activities) (Neuwald et al., 1999). These 
ATPase chaperones or chaperonins unfold and translocate globular substrates into the proteolytic 
chamber. Finally, degradation by self-compartmentalized proteases is processive, generating 
peptides of approximately 10–15 amino acids that, upon release from the protease chamber, are 
further degraded by cellular peptidases. Much of the biochemistry of these proteases is more 
thoroughly reviewed elsewhere (Gottesman, 2003). It is important to note that, for the most part, 
the characterization of these proteases has been performed with the nonpathogenic model 
organisms Escherichia coli and Bacillus subtilis. 
 
Lon protease is a cytoplasmic serine protease that associates to form homo-oligomer of six 
subunits in Gram-negative bacteria, with each subunit carrying both the protease active site and 
the ATP binding site (Botos et al., 2004a; Botos et al., 2004b; Goldberg et al., 1994; Gottesman, 
1996). It is known to degrade proteins that are damaged by stress and carry specific signals at 
both the N- and the C- termini (Gonzalez et al., 1998; Higashitani et al., 1997). Besides 
proteolysis, Lon has also been shown to display chaperone activity as well as promoting 
membrane protein assembly (Rep et al., 1996). Another ATP-dependent protease that exhibits 
chaperone activities is the FtsH/AAA family. This family of proteases are anchored to 
membranes but contain cytoplasmic domains with ATPase activity and Zn2+ metalloprotease 
active sites (Tomoyasu et al., 1995; Tomoyasu et al., 1993). Similar to Lon, it forms a homo-
Introduction 
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oligomer with both ATPase and protease active site in a single polypeptide (Tomoyasu et al., 
1995; Tomoyasu et al., 1993). 
 
Meanwhile, the heat shock locus gene products encode a cytoplasmic ATP-dependent protease, 
HslVU (ClpQY) (Rohrwild et al., 1996). HslV (ClpQ) forms hexamers that associate with each 
other as stacked rings flanked by hexamers of HslU (ClpY). The mechanism of degradation by 
HslVU is well reviewed by Groll et al (2005). The last family of protease we would like to 
discuss briefly before moving on to a more in-depth review on Clp protease is the bacterial 
proteasome. Bacterial 20S proteasome are present in Actinomycetes and composed of two 
heptameric β-subunit rings sandwiched between heptameric rings of α-subunits (Hu et al., 2006; 
Tamura et al., 1995). The catalytic subunits are similar in sequence and structure to eukaryotic 
proteasomes and the β-subunits have N-terminal threonines that form the active sites of the 
protease (Zwickl et al., 2000).  
 
1.3 Clp proteolytic machinery 
The Clp (caseinolytic protease) family of proteins is highly conserved throughout most 
prokaryotes as well as in the organelles of eukaryotes (Gottesman, 2003). These are two-
component proteases consisting of separately encoded ATPase and peptidase subunit. The first 
isolated members of this family were the ATP-dependent chaperone ClpA and the serine protease 
ClpP, whereby the former was found to promote degradation of casein when complexed with the 
latter (Hwang et al., 1988; Katayama et al., 1988; Maurizi et al., 1990a; Maurizi et al., 1990b). 
ClpX was later identified as an alternative chaperone to ClpA (Gottesman et al., 1993). Alone, 
ClpP is able to degrade only small peptides. Degradation of large or folded proteins require that 
they first be unfolded through ATP hydrolysis by the chaperone component. ClpA is absent in 
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Gram-positive bacteria but studies suggest that ClpP interacts with ClpC and ClpX instead 
(Kruger et al., 2000; Wiegert and Schumann, 2001). 
 
In the following sub-sections, we expound on the two components of the Clp proteolytic 
machinery, namely the ATPase and the serine protease ClpP. Furthermore, we discuss in greater 
depth about the requirement and modes of substrate recognition and the role of adaptor proteins 
that have previously been identified in the literature.  
 
1.3.1 Clp ATPase 
The Clp ATPases are members of the Clp/Hsp100 family of molecular chaperones that belongs to 
the AAA+ superfamily of ATPases typically carrying one or two nucleotide binding domains 
(Neuwald et al., 1999; Schirmer et al., 1996).  
 
Among the Clp ATPases, ClpA has been the most extensively studied. In E. coli, ClpA has a 
subunit Mr of 83,000 and possesses an intrinsic ATPase activity that is increased in the presence 
of ClpP and substrates (Hwang et al., 1988; Katayama et al., 1988). ClpA is purified as a 
monomer-dimer mixture, but addition of magnesium, ATP or analogs of ATP promotes 
association of ClpA to a hexamer with Mr 450,000 to 500,000 (Maurizi, 1991). ClpA has a basal 
ATPase activity that is activated 80 to 100% in the presence of ClpP and appropriate substrates 
(Gottesman and Maurizi, 1992). ClpA has two ATP-binding sites and based on in vitro 
mutagenesis, the first ATP-binding site is responsible for its hexamer formation, while the second 
is essential for ATP hydrolysis (Seol et al., 1995).  
 
Other ClpA paralogs include ClpE and ClpL (Frees et al., 2004). Although ClpB is homologous 
to the other Clp ATPases, it does not appear to associate with ClpP but instead functions as a 
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molecular chaperone that breaks apart aggregated proteins. ClpL may serve a function similar to 
ClpB in Gram-positive bacteria (Frees et al., 2004). Many of the ATPases also exhibit chaperone 
activities independently of their roles in proteolysis (Wawrzynow et al., 1996). 
ClpC from Bacillus subtilis has low intrinsic ATPase activity and depends on cofactors to gain 
chaperone activity (Kirstein et al., 2006; Schlothauer et al., 2003). MecA, the best characterized 
ClpC adaptor proteins, facilitates ClpC oligomerization for its subsequent ATPase activity, 
substrate recognition and interaction with ClpP (Kirstein et al., 2006). For further elaboration on 
the adaptor proteins, see Section 3.3. 
 
1.3.2 ClpP – the proteolytic component 
The ClpP protease, as its name suggests, degrades casein and other proteins only in the presence 
of ATP (Katayama et al., 1986). ClpP alone can rapidly cleave short (3- to 6-amino-acid) peptides 
and will also cleave longer unstructured polypeptides, such as oxidized insulin B chain 
(Gottesman and Maurizi, 1992).It is composed of two heptameric rings stacked back-to-back 
forming a tetradecamer with a central pore that contains fourteen catalytic triads (Maurizi et al., 
1990a; Maurizi et al., 1990b; Wang et al., 1997). The catalytic triads, each composed of the 
residues Ser-His-Asp, are accessible only to small peptides (20-30 amino acids) or unfolded 
proteins translocated by the chaperone component.  
 
To gain proteolytic activity, the ClpP multimer associates with one or two hexameric rings of Clp 
ATPases, forming the ClpP-containing proteolytic complex. The association is achieved through 
six loops, of which each is a tripeptide with the consensus sequence of IGF (Kim and Kim, 2003). 
Mutation in the IGF loops disrupts the interaction between ClpX and ClpP but do not affect ClpP 
activity. Mapping of the IGF loop onto a homolog of known structure suggests a model for ClpX-
ClpP docking (Figure 1.2) (Kim et al., 2001). In association with the proteolytic core, the Clp 
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ATPases are responsible for the recognition, unfolding and translocation of substrates into the 
ClpP degradation chamber (Sauer et al., 2004). ATP hydrolysis is not required for association 
between ClpA and ClpP; nonhydrolyzable analogs such as AMPPNP and adenosine-5'-
thiotriphosphate (ATP-γ-S) promote self-association of ClpA and formation of the ClpA-ClpP 





Figure 1.2 A. Structure of ClpP, viewed face-on with the hydrophobic pocket colored in cyan. B. Model for 
the docking of ClpX hexamer on to ClpP tetradecamer via the exposed IGF loop. (From Kim et al, 2001). 
C. The ClpATPase subfamilies (adapted from (Frees et al., 2007). The ClpATPases contain either one or 
two nucleotide binding domains (AAA-1, AAA-2) and the length of the spacing between these domains, as 
well as the presence of specific signature sequences (not indicated in the figure), form the basis for the 
subfamily classification ClpA, ClpB, ClpC, ClpE and ClpL (Ingmer et al., 1999; Porankiewicz et al., 1999; 
Schirmer et al., 1996). Functional domains include the P domain required for binding to ClpP (Kim et al, 
2001), the Zn binding domain involved in dimerization (Wojtyra et al., 2003) and the N1 and N2 domains 
proposed to be involved in protein binding (Barnett et al., 2005). In addition, a domain (UVR) resembling 
the interaction domain between the nucleotide excision repair proteins, UvrB and UvrC was identified in 







ClpP genes are generally present as single copy in eubacteria, but some organisms possess a 
multigenic ClpP family. For example, two clpP genes are present in Bacillus thuringiensis 
(Fedhila et al., 2002), four genes are present in Cyanobacterium synechococystis (Schelin et al., 
2002), and five genes are present in Streptomyces coelicolor (de Crecy-Lagard et al., 1999). In S. 
coelicolor, the clpP genes are organized as two bicistronic operons and one monocistronic gene, 
all located at different sites on the chromosome (de Crecy-Lagard et al., 1999). 
 
Despite several differences among ClpPs of different organisms, the overall assembly and 
construction of ClpP cylinder remains conserved. The major modification lies in the ‘core’ ClpP 
structure to facilitate specific functions that are suitable for the varied cellular environment of the 
different organisms (Yu and Houry, 2007).    
 
1.3.3 Interplay of Clp/HSP100 and adaptor proteins 
As mentioned in the previous section, the Clp ATPase belongs to the AAA+ superfamily of 
ATPases. AAA+ proteins are generally modulated by a group of otherwise unrelated proteins 
termed adaptor proteins. An adaptor protein serves as an accessory component to main proteins in 
a signal transduction pathway. Several adaptor proteins for bacterial Clp/HSP100 proteins have 
been identified and characterized. They exhibit a great diversity in sequence and structure and 
vary in size, but are usually rather small proteins (Dougan et al., 2003). Adaptor proteins 
specifically modulate the substrate recognition and/ chaperone activity of their partner AAA+ 
protein. For instance, the adaptor protein RssB (Studemann et al., 2003; Zhou et al., 2001) and 
SspB (Levchenko et al., 2000) target specific substrates to ClpX, while another adaptor protein 
ClpS changes the substrate specificity of ClpA (Dougan et al., 2003; Guo et al., 2002; Zeth et al., 
2002). These adaptor proteins generally bind to the N-domain and function as modulators to their 
partner proteins as such that in their absence, the partner proteins can still be fully active. In 
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contrast, ClpC of B. subtilis requires the presence of the adaptor protein MecA or its YpbH 
paralog for all its general activities which include chaperone activities and degradation of 
substrates (Schlothauer et al., 2003). MecA has also been demonstrated to control oligomerization 
of ClpC which leads to its activation (Kirstein et al., 2006). 
 
1.3.4 Substrate recognition 
The first step in the process of degradation by Clp proteolytic machinery is substrate recognition. 
Substrates are recognized by a specific motif in the native sequence or alternatively, be 
subsequently introduced as in the case of the SsrA tag (Flynn et al., 2003; Gottesman, 2003). 
Flynn et al. (2003) isolated fifty ClpXP substrates from E. coli (Table 1.2) and identified three N-
terminal (N-M1, N-M2, N-M3) and two C-terminal ClpX-recognition motifs (C-M1, C-M2). C-
M1 is the SsrA-like motif, the most prevalent C-motif and mostly contains the hydrophobic 
residues Ala, Val or Leu. C-M2 motif is slightly longer than C-M1 motif and bear resemblance to 
that of the MuA repressor. Among the N- motifs, N-M1 is the most conserved with a strict 
recognition motif. Meanwhile, N-M2 and N-M3 are less well conserved with N-M2 mainly 
comprising hydrophobic residues and N-M3 generally consisting of polar residues. The transfer 
of these motifs to stable proteins renders the protein susceptible for degradation. 
 
As mentioned above, substrate recognition can also proceed with the addition of a short sequence 
carrying the recognition motif. The SsrA tag is the most widely studied recognition sequence to 
date. SsrA is a highly hydrophobic protein tag added to the C-terminus of nascent proteins whose 
synthesis has been stalled at the ribosome (Keiler et al., 1996). It is encoded by tmRNA, also 




During transcription-translation process, there occur instances whereby mRNA which lacks a 
STOP codon, probably due to premature transcription termination or the activity of RNAses, 
cause an accumulation of stalled ribosomes (Keiler et al., 1996). The SsrA RNA rescues these 
ribosomes in a process termed trans-translation, in which an alanyl-tmRNA enters the empty A 
site of the ribosome causing the release of the truncated mRNA lacking a STOP codon. The SsrA 
RNA also adds 11 amino acid tag (AANDENYALAA) to the incomplete protein. Proteins tagged 
with the SsrA peptide are targeted for degradation. The C-terminal Ala-Ala residues are critical 
for SsrA recognition by ClpX, or other proteases (Gottesman et al., 1998; Keiler and Shapiro, 
2003). When the two C-terminal alanine residues are replaced with aspartate residues, the 
derivative SsrA/LDD has lower affinity for ClpX and ClpA and is not degraded by ClpAP or 
ClpXP (Levchenko et al., 1997). A study by Singh et al (2000) demonstrated the specificity of 
ClpX for the SsrA tag while no binding was observed for substrate carrying SsrA/LDD tag. 
However, the same study revealed that ClpAP was able to bind to both substrate carrying mutated 
SsrA/LDD tag as well as substrate with no tag. 
 
Analysis of the subtrates recognized by ClpXP reveal that many of these proteins are involved in 
a variety of biochemical pathway inside the cell including transcription factors, metabolic 
enzymes, and proteins involved in the starvation and oxidative stress response (Table 1.2, Flynn 
et al., 2003). This finding highlights the importance of Clp degradation machinery in regulating 









Table 1.2 ClpXP-associated proteins (adopted from Flynn et al., 2003). 
 
Proteins are grouped into functional categories based on annotations from the Swissprot and the general 
literature. Proteins with C-terminal sequences similar to those of the SsrA tag (C-M1) or the MuA tag (C-
M2) are marked. Proteins whose N-terminal peptides bind to ClpX strongly (++) or moderately (+) are 
marked. The N termini of the proteins that bind to ClpX are categorized as containing N motif 1 (N-M1), N 
motif 2 (N-M2) or N motif 3 (N-M3). a Proteins whose corresponding C-terminal peptides inhibit ClpXP 




Figure 1.3 Schematic representation of the trans-translation process. a) A ribosome is stalled at a 
mRNA leaving the A site empty. b) The aminoacyl-tmRNA (green) enters the A site. c) The tmRNA moves 
to the P site, displaces the tRNA and adds its alanine to the incomplete peptide. d) The original mRNA is 
released and tmRNA becomes the template for translation resulting in the addition of the SsrA tag to the 
peptide (green). e) After translation is completed, the ribosomal complex dissociates and the tagged peptide 
is targeted for degradation by ClpXP. (from Tawfilis, 2004) 
 
 
1.3.5 Modes of substrate recognition, unfolding and proteolysis 
The recognition of a particular substrate can be achieved in a number of methods and can be 
contributed by both the Clp ATPase and the adaptor protein. The N-terminal domain of ClpA and 
ClpX can interact directly with the substrate protein by recognizing the SsrA-tag (Flynn et al., 
2003). Alternatively, the adaptor protein could tether substrate and expose the recognition site for 
subsequent interaction with the ATPase as demonstrated by E. coli ClpX with its adaptor proteins 
SspB, UmuD or Rssb (Dougan et al., 2003; Levchenko et al., 2005; Neher et al., 2003; Siddiqui et 
al., 2004; Wah et al., 2003). The tethering increases the local substrate concentration leading to a 
10-fold increase in the degradation kinetics (McGinness et al., 2006). In B. subtilis, the N-
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terminal domain of the adaptor protein MecA is needed for the recognition and targeting of 
substrate proteins (Persuh et al., 1999; Schlothauer et al., 2003), whereas the C-terminal domain 
is necessary for the interaction with ClpC and the induction of the ClpC ATPase activity. 
 
The unfolding and subsequent translocation of a native protein requires the activity of the Clp 
ATPases. The hexameric ATPases bind in an asymmetric manner either on one or both axial sites 
of the double heptameric ClpP, as illustrated in Figure 1.4. Substrates are unfolded and 
translocated through the continuous Clp ATPase-ClpP channel down into the proteolytic cavity of 
ClpP (Ortega et al., 2002; Ortega et al., 2000; Schirmer et al., 1996). Clp mediated proteolysis 
requires high energy consumption, as ATP influences the stability of the Clp ATPase-ClpP 
complex (Singh et al., 1999) and is needed for the denaturing step to unfold the substrate and for 
the subsequent translocation (Kenniston et al., 2003). The variation in the ATP consumption is 
based on the stochastic nature of the unfolding process and the probability to successfully unfold 
the protein depends on the structural stability of the substrate (Kenniston et al., 2003; Martin et 
al., 2008).  
 
Figure 1.4 Schematic model of the various stages of the protein degradation process in the prokaryotic 




1.3.6 Self-compartmentalized bacterial proteases and pathogenesis 
The correlation between ATP-dependent proteases and virulence of gram-negative pathogens has 
been demonstrated by various studies. Jackson et al (2004) showed that ClpXP and Lon are 
required for the expression of Type III secretion systems (T3SS) in Yersinia pestis. T3SS are 
supramolecular structures that span bacterial inner and outer membranes and inject effectors into 
eukaryotic host cells (Mota and Cornelis, 2005). T3SS is closely associated with a variety of 
virulence phenotypes including invasion of epithelial cells and ability to kill macrophages. In 
Salmonella enterica serovar Typhimurium (S. Typhimurium), a signature-tagged transposon 
mutagenesis (STM) screen for mouse-attenuated mutants revealed the role of ClpP in the bacteria 
pathogenesis (Hensel et al., 1995). Furthermore, a clpX and two different clpP mutants were 
severely attenuated during monotypic infection of mice (Webb et al., 1999; Yamamoto et al., 
2001). In E. coli, the effects of clpP and clpX mutations on the stability of the stress response 
transcription factor RpoS (also termed sigma-38 or KatF) are well established (Hengge-Aronis, 
2002).  
 
Similarly, ATP-dependent proteases have been closely linked to the pathogenesis of gram-
positive bacteria. For instance, ClpC ATPase is implicated in the virulence of Listeria 
monocytogenes by promoting early bacterial escape from the phagosomal compartment of 
macrophages (Rouquette et al., 1998; Rouquette et al., 1996). Another heat shock protein ClpE is 
also involved in the virulence of L. monocytogenes, acting synergistically with ClpC in cell 
division under conditions of nutrient and energy deprivation at elevated temperatures (Nair et al., 
2000). In addition, a clpP mutant was severely growth impaired at 42ºC (Gaillot et al., 2000), 
suggesting a general stress response in L. monocytogenes. In Streptococcus pneumonia, STM 
screens identified ClpL and ClpC ATPases as an important factor for virulence during a mixed 
infection in mice (Hava and Camilli, 2002; Polissi et al., 1998). Few studies have also pointed out 
Introduction 
 20 
the requirement of ClpP for thermotolerance, development of competence and virulence of 
Streptococcus pneumonia (Chastanet et al., 2001; Robertson et al., 2002). Similar to several 
pathogens described previously, the first hint of ATP-dependent protease involvement in 
pathogenesis of Staphylococcus aureus is derived from an STM study. Using a mouse model of 
bacteraemia, ClpX was shown to be required for full virulence of S. aureus (Mei et al., 1997). 
Another S. aureus study demonstrated the requirement for ClpC ATPase for resistance to 
hydrogen peroxide, post heat shock recovery and activity of the tricarboxylix acid (TCA) cycle 
enzyme aconitase (citB) (Chatterjee et al., 2005).    
 
In non-pathogenic model organism Bacillus subtilis, loss of clpP causes pleiotropic effects, with 
distinct morphological and biochemical features such as highly filamentous and non-motile cells 
(Msadek et al., 1998). In the absence of clpP, expression of the key early sporulation genes is 
almost completely inhibited (Porankiewicz et al., 1999).  
 
In summary, energy-dependent proteolysis is likely to be important during growth, development 
and pathogenesis of various bacteria. These proteases may prove to be ideal targets for 
antimicrobial drug development. Recently, a group at Bayer discovered acyldepsipeptides 
(ADEPs), which, upon addition to ClpP of Bacillus subtilis, allow the protease to degrade folded 
native proteins in the absence of its cognate chaperone (Brotz-Oesterhelt 2005). ADEPs cause 
unregulated proteolysis by ClpP, subsequently, triggering cell death in Gram-positive bacteria, 
including multidrug resistant S. aureus (Brotz-Oesterhelt 2005). Hence, targeting protease and 






1.3.7 Mycobacterium tuberculosis and its protein degradation machinery 
M. tuberculosis is a Gram positive bacterium with a high G+C-rich genome (Cole et al., 1998). 
The characteristic features of the tubercle bacillus include its slow growth, dormancy, complex 
cell envelope, intracellular pathogenesis and genetic homogeneity (Cole et al., 1998). The 
generation time of M. tuberculosis, in synthetic medium or infected animals, is typically 24 
hours. This contributes to the chronic nature of the disease, imposes lengthy treatment regimens 
and represents a formidable obstacle for researchers. The complete genome sequence of 
Mycobacterium tuberculosis, has been determined and analysed and comprises 4,411,529 base 
pairs (http://genolist.pasteur.fr/TubercuList/) and (http://cmr.jcvi.org/tigr-
scripts/CMR/GenomePage.cgi?database=gmt). M. tuberculosis differs radically from other 
bacteria in that a very large portion of its coding capacity is devoted to the production of enzymes 
involved in lipogenesis and lipolysis, and to two new families of glycine-rich proteins with a 
repetitive structure that may represent a source of antigenic variation. 
 
M. tuberculosis possesses clpX, clpB, and 2 copies of clpc genes, namely clpC1 and clpC2, which 
are located in different operons (http://genolist.pasteur.fr/TubercuList/). clpC1 is conserved in M. 
tuberculosis, M. leprae, M. bovis and M. avium paratuberculosis and predicted to be essential for 
in vivo survival and pathogenicity (Ribeiro-Guimaraes and Pessolani, 2007). Singh et al. (2006) 
used a system termed mycobacterial protein fragment complementation (M-PFC) to show 
protein-protein interaction in mycobacterium and demonstrated that M. tuberculosis ClpC1 
selectively associated with the ClpP2 protease subunit. In addition, M. tuberculosis ClpC1 was 
demonstrated to display inherent ATPase activity and also functions like a chaperone in vitro 




In M. tuberculosis, no adaptor protein has been identified for the HSP100/Clp proteins. Whether 
adaptor protein is a requirement for functional activity of these proteins are currently unknown.   
 
There are 2 isoforms of ClpPs in M. tuberculosis; ClpP1 and ClpP2. The structure of M. 
tuberculosis ClpP1 has been elucidated and it was found that there exist protruding loops in the 
αA helix at the N-terminal which renders the axial pores smaller compared to those in other 
ClpPs. This observation was hypothesized to preclude entry of even small peptides and thus the 
lack of peptidasic activity of the purified ClpP1. The active sites of ClpP1 were purified as 
inactive conformation and further processing of the enzyme may be required to obtain the active 
form (Ingvarsson et al., 2007). The closest homologues of the M. tuberculosis ClpP1 and ClpP2 
are the ClpP1 and ClpP2 proteins of S. coelicolor, suggesting that the duplication of genes 
occurred before the divergence of the Mycobacteriaceae and the Streptomycetes (de Crecy-
Lagard et al., 1999). It is worth noting that in S. coelicolor, the presence of independently folded 
ClpP2 homo-oligomer is needed to obtain a processed ClpP1 homo-oligomer and vice versa 
(Viala and Mazodier, 2002). The same paper also suggested an alternative hypothesis in which 
the two proteins would form a hetero-tetradecamer in order to become active (Viala and 
Mazodier, 2002).    
 
M. tuberculosis ClpP1 is found to form stable heptamers under normal conditions (Ingvarsson et 
al., 2007) and tetradecamer upon crystallization. The structure of ClpP2, on the other hand, has 
not been elucidated. Since the two forms belong to the same operon, their predominant 
physiological assembly could possibly be hetero-oligomer. 
 
Correspondingly, there have been a few studies that examine the role of protease in the 
pathogenesis of M. tuberculosis. The persistence of M. tuberculosis in macrophages has been 
associated with the presence of nitric oxide (NO) resistance genes in M. tuberculosis. Darwin et 
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al. (2003) screened NO-sensitive mutants of M. tuberculosis and identified insertions in the 
putative proteasome-associated genes, mpa and pafA. A further study by the same group 
demonstrated that mpa and pafA mutants are severely attenuated in a mouse model of infection 
(Darwin et al., 2005). Mpa is an ATPase that forms hexamers like the Clp ATPase. Meanwhile, 
pafA, despite bearing no resemblance to known proteins, has been suggested to play a role in 
substrate targeting to the proteosome (Darwin et al., 2003). Mutants in the pafA gene, which is 
part of an operon downstream of the proteasome genes, show similar effects as the ATPase 
mutant in M. tuberculosis (Darwin et al., 2003; Pearce et al., 2006). In addition, both leprosy and 
tuberculosis patients have been shown to develop antibodies specifically directed against ClpC 
from the causative pathogen (Misra et al., 1996). 
 
 
1.4 Preliminary data 
This section is attributed to the preliminary or accessory data performed by Novartis group and 
NITD members that either leads to and/or support the data obtained from this thesis.  
1.4.1 Isolation and characterization of Compound X 
Compound X was isolated from an actinomycetes strain, taken from the Novartis strain 
collection. The bacteria were grown in a fermentor and Compound X was extracted and purified 
from culture broth. Compound Y, W, V were obtained after modification of functional groups 
from compound X. Stocks from those compounds were prepared as 5 mM in 90% dimethyl 
sulfoxide (DMSO; Acros Organics) and stored at 4°C prior to use. (NITD, unpublished data) 
 
Compound X was evaluated for its inhibitory activity against M. tuberculosis. Comparison of the 
MIC50 and MBC90 of Compound X with standard frontline TB drugs (Table 1.3) clearly showed 
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that the inhibitory and bactericidal activity of Compound X against M. tuberculosis is better than 
streptomycin, isoniazid and moxifloxacin.  However, Compound X displayed higher MIC50 and 
MBC90 than rifampicin. Interestingly, Compound X also showed excellent activity against several 
single-drug and multidrug resistant clinical isolates of M. tuberculosis (Table 1.4) (NITD’s 
results, unpublished data).  
 
Table 1.3 Inhibitory and bactericidal activity of Compound X and other standard anti-TB drugs against M. 
tuberculosis  
 
Compound/drug Melocular weight  MIC50 (µM) MBC90 (µM) 
Compound X 1043.32 0.048 0.288 
Rifampicin 822.97 0.006 0.019 
Isoniazid 137.14 0.248 0.394 
Streptomycin 581.6 0.576 3.908 















Table 1.4 MIC values for Compound X against various drug resistant strains of M. tuberculosis  
  MIC50 (mg/L)  
Strain Compound X INH Gatifloxacin 
H37Rv (ATCC 27294) 0.008 0.045 0.03 
Beijing MDR 1 0.008 0.06 0.015 
Beijing MDR 2 0.003 2 0.03 
Beijing W MDR 0.125 1 0.37 
Beijing F29 MDR 1 0.06 0.25 0.03 
Beijing F29 MDR 2 0.003 0.37 0.03 
INHr SDR 0.008 4 0.015 
SMr SDR 0.008 0.09 0.03 
RIFr SDR 0.03 0.03 0.045 
PZAr SDR 0.03 >8.0 0.045 
Clinical MDR 1 0.008 2 0.03 
Clinical MDR 2 0.03 4 0.015 
Clinical MDR 3 0.008 0.125 0.015 
Clinical MDR 4 0.008 2 0.015 
Clinical MDR 5 0.015 2 0.03 
 
MDR, multidrug resitance, SDR, single-drug resistance, INH, isoniazide, SM, streptomycin, RIF, 
rifampicin, PZA, pyrazinamide. All MIC determinations were done twice and the average values are 







1.4.2 Frequency of spontaneous Compound X-resistant mutants in mycobacteria 
Point mutation in the target genes are known to be the principal mechanism of drug resistance in 
M. tuberculosis (Cole and Telenti, 1995; Musser, 1995). To assess the frequency mutation at 
which resistance to Compound X might occur, we spread M. bovis BCG onto plates containing 
either Compound X or the standard antituberculosis drugs rifampicin and isoniazid and compared 
the rate at which resistant colonies appeared. We tested each drug at ten times its MIC50 
(rifampicin 0.1 µM; isoniazid 0.34 µM and compound X 0.5 µM).  
 
Briefly, wild-type M. tuberculosis, M. bovis BCG or M. smegmatis cultures were grown in 7H9 
broth to an OD600 of 0.4–0.5, and 1010 cfu mL-1 was evenly spread onto drug-free 7H10 agar 
plates or onto 7H10 plates containing different concentrations of Compound X (5X and 10X 
MIC). Plates were incubated at 37ºC for 4–6 weeks, and the colonies were counted. The 
frequency at which spontaneous drug resistant mutants arose in a given culture was calculated as 
the ratio of the average number of colonies that grew on drug-containing plates to those growing 
on drug-free plates. In a similar manner, spontaneous rifampicin-resistant mutants of MTB and 
BCG were isolated at 10X MIC (0.05 mgL-1).  
 
The frequency of colonies resistant to rifampicin was about 10-7, and the frequency of colonies 
resistant to isoniazid was about 10-6; both of these values are within the range predicted by 
previously published work (Cole and Telenti, 1995; David and Newman, 1971; Sander and 
Bottger, 1999). Numerous microcolonies were observed on all plates containing Compound X 
that were originally inoculated with 109 BCG cells. Several colonies were picked and again 
grown in liquid media with or without Compound X. The cultures without Compound X grew 
within a week at 37ºC, whereas none of the culture grew after 3 weeks in the presence of 0.5 µM 
Compound X. These data suggest that the frequency of mutations for resistance to Compound X 
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is less than 10-10 and that further development of drugs of this class will not be rapidly 
undermined by selection of resistant strains of M. tuberculosis (NITD’s results, unpublished 
data). 
 
1.4.3 Compound X bind to ClpC1 (Esther Schmitt et al., unpublished data) 
To search for the molecular target of Compound X, cell lysate of M. bovis BCG was passed 
through a Compound X affinity column (Figure 1.5). Only one protein remained specifically 
bound, which we identified as a ClpC1 by mass spectrometry analysis. The interaction can be 
competed by 5 µM free Compound X pre-incubated with the protein lysate (Figure 1.6). No 
specific interaction was observed with protein lysate from HeLa cells or Staphylococcus protein 
lysates (data not shown). ClpC1 is a member of the Clp/Hsp100 family of molecular chaperones 
associated with various cellular activities. M. tuberculosis posseses ClpC1 as an orthologue of E. 
coli ClpA and also possesses ClpC2 and ClpX (Shanklin et al., 1995). In our experiment only 
ClpC1 was retained in the Compound X affinity column. Thus ClpC1 is the only member of the 
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Figure 1.5 Adsorption of M. bovis BCG cell lysate to a Compound X affinity column (SDS-PAGE 






Figure 1.6 SDS-PAGE SYPRO Ruby stained of protein pull down with different protein concentrations of 
M. bovis BCG lysate and quantification of ClpC1 band. On the left figure, each lane represents the different 
mixture of either blank or Compound X as the resin used, BCG lysates and pre-incubation with Compound 
X. The right figure shows the volume of the band that corresponds to ClpC1, as a percentage of total 
densities of the bands in that specific lane. 
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Aims of Thesis 
 
The increasing incidence of tuberculosis has become a major concern that requires our immediate 
attention. The worldwide problem caused by TB and the lack of new drugs in the market makes it 
imperative to have new anti-TB drugs with novel biological target. However, no new anti-TB 
drugs with novel target have been discovered in the past 40 years. There are only a handful of 
anti-TB drug candidates that entered clinical trials in recent years.  
 
One approach to discover a new anti-TB drug is to screen libraries for active compound and then 
define its target. To achieve this, whole-cell screen of natural product library at Novartis was 
carried out to search for growth inhibitors of Mycobacterium bovis, with the goal of finding a new 
hit compound with a novel target in mycobacteria. Indeed, the screening of 12,000 natural 
compounds led to the identification of a hit, Compound X.  
 
A preliminary study to identify the target of Compound X was carried out to elucidate the 
mechanism of action of this compound. Using affinity chromatography, a pull down assay was 
performed and ClpC1 was identified as the putative target for Compound X in mycobacteria. 
Keeping this in mind, discussions from the previous sections allow us to recognize the important 
role of protease in pathogenicity of bacteria, in particular the Clp protease. In M. tuberculosis, the 
role, structure and function of Clp protease have not been fully elucidated. Given its novelty and 
proteolytic importance, Clp could potentially serve as a drug target in mycobacteria.  
 
Based on these findings, we aimed to: 1) confirm ClpC1 as the target of Compound X in 
mycobacteria; 2) elucidate the mechanism of action of Compound X. To achieve these aims, we 
first attempted to generate clpc1 deletion mutant in M. bovis BCG and check for the activity of 
Compound X on this mutant. Next, we expressed and purified the recombinant proteins and 
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assessed their individual functionality in the presence of Compound X by developing in vitro 
biochemical assays. These include the ATPase assay on ClpC1, peptidase assay on ClpP1 and 
ClpP2, and finally proteolytic assay on the enzyme complex. In conjunction to this, a cell-based 
assay using Green Fluorescent Protein (GFP) as a reporter gene was also developed to analyze the 
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2.1. Bacterial strains, Growth conditions 
The slow growing Mycobacterium bovis BCG Pasteur and the fast growing Mycobacterium 
smegmatis (mc2155) were cultured in Middlebrook 7H9 broth (Becton Dickinson, USA) 
supplemented with 0.5% glycerol, 0.05% Tween-80 and 10% (v/v) Albumin-Dextrose-Saline 
(ADS: 950 ml dH2O, 8.1 g NaCl, 50 g Bovine Serum Albumin Fraction V (Roche, Switzerland), 
20 g D-dextrose) or grown on Middlebrook 7H10 or 7H11 agar plates (Becton Dickinson, USA) 
supplemented with 0.5% glycerol and 10% (v/v) oleic acid-dextrose-albumin-catalase enrichment 
(OADC; Becton Dickinson, USA). When required, Middlebrook 7H9 broth or Middlebrook 7H10 
or 7H11 agar plates were supplemented with 25 µgml-1 kanamycin or 50 µgml-1 hygromycin for 
antibiotic selection. 
 
Escherichia coli TOP10 cells (Invitrogen, USA) were used in cloning experiments and E. coli 
Tuner™(DE3) (Merck) or E. coli BL21-CodonPlus®(DE3)-RP (Stratagene) was used for protein 
expression and purification. All E. coli strains were grown in Luria-Bertani (LB) (Becton 
Dickinson, USA) broth or on LB agar plates. When required, LB broth and LB agar plates were 
supplemented with 5 µgml-1 gentamicin (Sigma, USA), 50 µgml-1 kanamycin (Sigma, USA), 150 
µgml-1 hygromycin (Roche, Switzerland) or 50 µgml-1 chloramphenicol (Sigma, USA). 
 
2.2 Antibacterial activity of Compound X 
The MIC50 (Minimum Inhibitory Concentration) in this study is defined as the lowest 
concentration of compound that inhibited 50% of the wild type strain. Different dilutions of the 
compound of interest were prepared in 96-well plate. Meanwhile, cells were grown to log phase 
(OD600nm ~ 0.2-0.4) at 37ºC in 7H9 medium containing the appropriate antibiotic selection 
markers. The cultures were diluted and added into the compound dilutions to a final optical 
density of 0.02. The plate was incubated at 37ºC for approximately 5 days for M. bovis BCG and 
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2 days for M. smegmatis, until the cells growing in the medium containing no compound reach 
OD600nm ~ 0.2. The cell optical density was measured by the absorbance reading at OD600nm. A 
graph of OD600nm versus concentrations of compound was plotted using statistical software Prism 




2.3 Construction of M. bovis BCG clpC1 deletion mutant  
2.3.1 Construction of vectors 
To generate the clpC1 deletion mutation on M. bovis BCG, the sequence data base 
(http://genolist.pasteur.fr/BCGList/) was utilized to generate two primers pairs: ClpC1 5’flanking 
(LEFT) and ClpC1 3’flanking (RIGHT) (See Section 2.8 for list of primers), which were 
employed to amplify the upstream LEFT and the downstream RIGHT arm flanking the clpC1. 
After sequencing, the resulting flanking fragments were cloned directionally into vector 
pYUB854 (also called p854) (Bardarov et al., 2002) digested with kpnI and XbaI (LEFT arm) and 
with HindIII and XhoI (RIGHT arm). The resulting cosmid p854/ClpC1 does not replicate in 
mycobacteria and carries 50 bp of the 5' and 3’ of the 2.5 kb of clpC1 gene. The marker gene 
PAg85-lacZ-Phsp60-sacB from pGOAL17 (Parish and Stoker, 2000) was then cloned into the unique 
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2.3.2 Isolation of single cross-over strain (clpC1-sco strain). 
Approximately 2 µg vector DNA (p854/ClpC1) (Figure 2.3.1.1) was pretreated with 70 J UV 
light  cm-2 to stimulate homologous recombination and electroporated into M. bovis BCG  (Hinds 
et al., 1999  ; Parish et al., 1999 ) as described below. Single cross-over strains were selected 
using 75 µgml-1 hygromycin. PCR primers used to characterize single crossover clones are 
indicated in Section 2.8 (list of primers). 
 
2.3.3 Isolation of double cross-over strains from clpC1-sco strain. 
The single cross-over strain (clpC1-sco) was streaked out onto media without antibiotics and 
incubated for 2 weeks at 37 °C. A loopful of cells was resuspended in liquid media by vortexing 
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with 1 mm glass beads. Serial dilutions were plated onto 2% (w/v) sucrose plates plus hygromycin 
and 40 µgml-1 X-Gal. Plates were incubated at 37 °C for 4–6 weeks. Sucrose-resistant colonies 
were used to confirm the clpC1 inactivation by PCR. 
 
2.3.4 Preparation of electrocompetent of M. bovis BCG and M. smegmatis  
One hundred milliliters of M. smegmatis cells were grown to reach OD600 = 0.4-0.6. The cells 
were harvested by centrifugation at 3,000rpm for 10 minutes, followed by washing with 25 ml, 10 
ml and 5 ml of ice-cold 10% glycerol. Finally, the cells were resuspended in 1ml of ice-cold 10% 
glycerol. Aliquots of the cells were prepared by transferring 200 µl of cells into cryotubes. The 
cells were ready for use or stored frozen at -80°C. Similar procedure was carried out for M. bovis 
BCG with slight modification on the washing step. Instead of using ice-cold glycerol, dH2O 
containing 0.05% Tween 80 at room temperature was used to wash the cells. 
 
2.3.5 Transformation into electro-competent M. bovis BCG and M. smegmatis cells 
Plasmid DNA (500 ng - 1 ug) was added to 200 µl of electrocompetent cells in 0.4 mm cuvettes 
pre- incubated at 37°C. The cuvette was placed in BioRad Gene Pulser and the content was 
pulsed at 2500 mV, 1000 Ω, 25 µF. Immediately, the cells were recovered in 5 ml of 7H9 
medium and incubated at 37°C for 2 hours on shaker set at 200rpm. The transformants were 
diluted 10x, 100x and 1000x before plating on Middlebrook 7H11 agar plates containing 
selection antibiotic marker. The plates were incubated at 37°C for 3-5 days for M. smegmatis and 
approximately 20 days for M. bovis BCG.  
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2.4 Isolation and characterization of Clp proteins as putative target of Compound X 
2.4.1 Sequence alignment of clpC1, clpP1 and clpP2 
Sequence alignments were performed using ClustalW2 obtained from EMBL-BI website, under 
Sequence Analysis Tools. The Mycobacterium tuberculosis and Mycobacterium bovis BCG 
sequences were obtained from TubercuList Web Server while Mycobacterium smegmatis 
sequences were obtained from JCVI-TIGR database. Alignments of the genomic regions were 
performed at JCVI-CMR server. The sequence alignments for clpC1, clpP1 and clpP2 are 
available at Supplementary Data. 
 
2.4.2 Expression and purification of ClpC1, ClpX, ClpP1 ClpP2 and GFP-ssrA  
2.4.2.1 Sub-cloning and creation of expression vectors 
M. tuberculosis clpC1, clpX, clpP1, clpP2 as well as untagged gfp, gfp_SsrA/LAA, and 
gfp_SsrA/LDD were cloned individually into an expression vector for subsequent protein 
expression and purification. clpP1 and clpP2 were PCR-amplified HotStar HiFidelity DNA 
Polymerase from Mycobacterium tuberculosis (H37RV) genomic DNA while GFP-wt, 
GFP_SsrA/LAA and GFP_SsrA/LDD were PCR-amplified from pMind_GFP plasmid DNA 
(from Srinivasa Rao-NITD, personal communictaion) using the given oligonucleotides containing 
the respective restriction sites. The list of oligonucleotides and restriction sites used for each gene 
cloned is given in Section 2.8 (list of primers). The gene product was cloned into a 
pCR®TOPO2.1® vector and transformed into chemically competent E. coli Top10 cells. A 
colony was inoculated into 5 ml of LB broth, followed by plasmid extraction according to the 
QIAprep Spin Miniprep kit (QIAGEN) protocol. The plasmid was checked for correct sequence. 
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The plasmid was digested with the appropriate restriction enzymes. The digested product was 
ligated into the corresponding restriction sites of pNAT745 (4323bp, Gentamicin resistance 
marker, Figure 2.2) and transformed into chemically competent E. coli Top10 cells. The cells 
were plated on LB agar and incubated at 37°C overnight. A colony was inoculated into 5 ml of 




Figure 2.2 Map of pNAT745 plasmid and pNAT8 series used as entry vector and destination vector, 
respectively, in the Gateway-based vector system for protein expression and purification. GemR: 
Gentamicin resistance marker, KanR: Kanamycin resistance marker. 
 
The gene was shuttled from the plasmid, now an entry clone, to each of the eight in-house 
destination vectors, designated pNAT8 series (Figure 2.2), using the Gateway® LR ClonaseTM 
Enzyme mix (Invitrogen) and transformed into chemically competent Tuner™(DE3) (Merck) or 
BL21-CodonPLus®(DE3)-RP cells (Stratagene). For the list of destination vectors, see Table 2.1.  
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Table 2.1 Novartis in house Gateway destination vectors carrying His-tag and various solubility-enhancing 
tags. Molecular weight of the expressed tags (inclusive of His-tag) are indicated.  
Name N-terminal tag (in addition to His-tag) 
Molecular 
weight (kDa) 
pHisKan5 / pNAT80 None 5.0 
pTrxKan5 / pNAT82 Thioredoxin 16.8 
pMBPKan5 / pNAT83 Maltose binding protein 45.8 
pUbiKan5 / pNAT84 Ubiquitin 13.6 
pRbxKan5 / pNAT85 Rubredoxin 11.0 
pNusKan5 / pNAT86 N-utilization substance 59.9 
pZZKan5 / pNAT1052 Protein A IgG binding soluble domain 19.5 
pGGKan5 / pNAT1058 Protein G Ig binding domain B1 19.0 
 
 
2.4.2.2 Transformation into chemical-competent E. coli Top10 cells using heat-shock treatment 
Frozen chemical-competent E. coli Top10 cells were thawed on ice. Plasmid DNA (500 ng – 1 
ug) was added to the cells and incubated on ice for 5 minutes followed by heat-shock treatment at 
42°C for 40 seconds and 2 minutes incubation on ice. The cells were recovered with 500 ml of 
LB broth and incubated at 37°C for 1 hour on shaker set at 200rpm. The cells were plated on LB 
agar containing selection antibiotic marker and incubated at 37°C overnight. The next day, a 
colony was inoculated into 5 ml of LB broth containing the selection antibiotic marker. 
 
2.4.2.3 Small scale protein expression and purification 
For each gene product, cells from each of the constructs from different destination vectors were 
grown to 37ºC to OD600 = 0.3-0.6 in LB broth supplemented with 50 µgml-1 kanamycin. When 
BL21-CodonPlus®(DE3)-RP cells were used, additional 50 µgml-1 chloramphenicol was added 
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into the medium. Protein expression was induced with 0.1 mM isopropyl 1-thio-β-D-
galactopyranoside (Sigma) for 18h at 18ºC. Cells were collected by centrifugation. The cell pellet 
was resuspended in buffer containing 20 mM Tris-HCl pH8.0, 300 mM NaCl and 20 mM 
Imidazole with 10 μlg-1 pellet LysonaseTM Bioprocessing Reagent (Novagen) and lysed by 
sonication (BRANSON Digital Sonifier). The solution was centrifuged at 13,200rpm for 10 
minutes, and the supernatant was loaded onto Ni NTA spin columns (Qiagen). The pellet from 
centrifugation was solubilized with 20 mM Tris-HCl pH7.5, 8 M urea, 300 mM NaCl and 10 mM 
imidazole to form the ‘insoluble’ fraction. A portion of sample was taken from the supernatant to 
form the ‘soluble’ fraction. The proteins were eluted from the Ni NTA spin columns with 20 mM 
Tris-HCl pH7.5, 300 mM NaCl and 400 mM imidazole. The insoluble fraction, soluble fraction 
and the protein eluted were analyzed with sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) to obtain a small scale protein expression and purification profile. 
Supported by the profiles, the best construct was selected based on yield, solubility and purity for 
large scale protein expression and purification. 
 
2.4.2.4 Large scale protein expression and purification 
Cells were grown at 37ºC to OD600 = 0.3-0.6 in LB broth supplemented with 50 µgml-1 
kanamycin for Tuner™t(DE3) competent cells and 50 µgml-1 kanamycin. When BL21-
CodonPlus®(DE3)-RP cells were used, additional 50 µgml-1 chloramphenicol was added into the 
medium. Protein expression was induced with 0.1 mM isopropyl 1-thio-β-D-galactopyranoside 
(Sigma) for 18h at 18ºC. Cells were collected by centrifugation. The cell pellet was resuspended 
in buffer containing 20 mM Tris-HCl pH8.0, 300 mM NaCl and 20 mM Imidazole with 10 μlg-1 
pellet LysonaseTM Bioprocessing Reagent (Novagen) and lysed by sonication (BRANSON 
Digital Sonifier). After centrifugation at 8,000rpm for 15min, the supernatant of the lysate was 
loaded into a HisTrap HP 5 ml (GE Healthcare) column using the AKTA FPLC (Amersham 
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Biosciences) system. Loosely bound proteins were washed with buffer containing 20 mM Tris-
HCl pH8.0, 300 mM NaCl and 58 mM Imidazole and bound protein was eluted with buffer 
containing 20 mM Tris-HCl pH8.0, 300 mM NaCl and 400 mM Imidazole. The buffer of the 
eluate was exchanged with the appropriate storage buffer using a PD-10 Desalting Column 
(Amersham Biosciences). For purified ClpC1, the storage buffer used contains 200 mM KCl, 20 
mM Tris-HCl pH8.0, 10 mM MgCl2, 1 mM DTT, 10% glycerol. For the other purified proteins, 
the storage buffer composition was as follow: 50 mM Tris-HCl pH7.5, 100 mM KCl, 1 mM 
EDTA, 10% glycerol. The protein was incubated with PrescissionTM Protease (GE Healthcare) at 
4ºC for 48 hours to cleave the Histidine tag. The protein was further purified by size exclusion 
chromatography on a HiLoad 16/60 Superdex-200 column (Amersham Biosciences) and 
concentrated in a Vivaspin concentrator (Vivascience, 10kDa molecular weight cut-off). The 
purified protein was identified by SDS-PAGE and the concentration of the protein was estimated 
using the BCA Protein Assay Reagent (Thermo Fisher Scientific, USA). 
 
2.4.2.5 SDS PAGE 
Pre-cast NuPAGE® Novex® Bis-Tris Mini Gels 4-12% (Invitrogen, USA) were used for all SDS 
PAGE analysis, together with NuPAGE® MES or MOPS SDS running buffer for different 
molecular weight separation ranges. For the sample preparation, equal volumes of 1 M 
dithiothreitol (DTT) and 4X NuPAGE LDS Sample Buffer (Invitrogen) were mixed and added to 
equal volume of sample. The solution was heated at 70°C for 10 minutes before loaded into the 
wells of the pre-cast gel. Novex® Sharp Protein Standard was used for estimation of protein 
molecular weight sizes. Gel electrophoresis was run using XCell SureLock™ Mini Cell 
(Amersham Biosciences) at 200 Volts, 400 mA for 35 minutes when MES running buffer was 
used and 55 minutes when MOPS running buffer was used. Following electrophoresis, gel was 
removed from the plastic cast and rinsed with dH2O. Gel was then incubated with staining 
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solution for 1 hour at room temperature and with destaining solution (40% (v/v) ethanol, 10% 
(v/v) acetic acid, and 50% (v/v) dH2O) for another hour until the stain from the gel was 
completely removed. Finally, the gel was rinsed with dH2O. To prepare stock staining solution 
(0.2%), one tablet of PhastGel™ Blue R (GE Healthcare Life Sciences) was dissolved in 80 ml of 
dH2O and 120 ml of methanol and mixed. To prepare final working staining solution (0.1%), one 
part of stock solution was mixed with equal volume of 20% (v/v) acetic acid in dH2O. 
 
2.4.3 Biochemical assays to assess the activity of Clp proteins 
2.4.3.1 ATPase activity of M. tuberculosis ClpC1 and ClpX 
ATPase activity was measured by monitoring the released phosphate level using BIOMOL 
GREENTM Reagent (BIOMOL International Inc.). Basal ATPase activity was measured by 
incubating 0.5 µM ClpC1 with varying ATP concentrations at room temperature for 1 hour, 2 
hours and 4 hours in a reaction buffer containing 50 mM Tris-HCl at pH7.5, 100 mM NaCl, 100 
mM KCl, 10 mM MgCl2, 2 mM DTT, and 10% glycerol to a final volume of 50 µL. At each time 
point, 100 µL BIOMOL GREENTM Reagent was added to the reaction mixture, followed by 20-30 
minutes incubation at room temperature. The intensity of green colour development was 
quantified by measuring the absorbance at OD620nm and converted to the amount of phosphate 
released using the phosphate standard curve. A graph of phosphate released versus concentration 
of ATP was plotted with Prism (GraphPad, USA). 
 
For the effect of Compound X on the ATPase activity of ClpC1, we used similar experimental 
set-up as described above with the addition of varying concentrations of Compound X. A graph 
of increase in phosphate released versus concentration of Compound X was plotted with Prism, 
with basal level subtracted. At another assay, the ATPase assay was performed with different 
analogues of Compound X having various MIC50 values. Similar experimental set-up as described 
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above was conducted for each of the Compound X analogues: Compound Y, Compound W and 
Compound Z. 
 
2.4.3.2 Peptidase activity of M. tuberculosis ClpP1 and ClpP2 
Peptidase activity was measured using the fluorogenic peptide N-succinyl-leucine-tyrosine-
amidomethlycoumarin (N-suc-leu-tyr-AMC) (Sigma, USA) as a substrate. Before reaction, 
fluorescent AMC is quenched by the presence of the peptide. Upon cleavage by peptidase, the 
fluorescent AMC is released and can be quantified. In this assay, different concentrations of 
purified ClpP1 (0.25 μM, 0.5 μM) and/or purified ClpP2 (0.25 μM, 0.5 μM) were incubated with 
100 μM of the substrate at 37ºC in a buffer containing 50 mM Tris-HCl pH 8.0, 25 mM MgCl2, 
100 mM KCl, and 2 mM DTT. After 1 hour, the fluorescence was measured in using Safire2 at 
442 nm following excitation at 353 nm. 
 
2.4.3.3 Proteolytic activity  of ClpC1-ClpP complex with β-casein as substrate 
We incubated 5-15 µM of β-casein (Sigma-Aldrich, USA) with 1 µM ClpC1 and 1 µM ClpP1 or 
1 µM ClpP2 or both in buffer containing 200 mM KCl, 50 mM Tris-HCl pH7.5, 10 mM MgCl2, 
10% glycerol and 1 mM DTT, with an ATP-regeneration system (5 mM ATP, 16 mM creatine 
phosphate, 6 µgml-1 creatine phosphokinase). Mixtures were incubated at 37ºC up to 200 min and 
at different time points, sample was withdrawn and analyzed using SDS-PAGE.  
 
2.5 Effect of compound X on the degradation of GFP-ssrA tag in M. smegmatis 
2.5.1 Construction of GFP-ssrA tag plasmids 
gfp genes with or without the SsrA recognition tag were over-expressed in M. smegmatis using 
tetracycline-inducible system pMind plasmid (Blokpoel et al 2005). Briefly, each gene was PCR-
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amplified using HotStar HiFidelity DNA Polymerase from pMind-GFP plasmid (obtained from 
Srinvasa Rao-NITD, personal communication) using the given oligonucleotides containing the 
respective restriction sites. The SsrA recognition tag was added to the 3’-end of the 
oligonucleotides used to PCR the gene. The oligonucleotides for the creation of M. smegmatis 
mutants overexpressing GFP with SsrA tag are GFP_SsrA/LAA_om and GFP_SsrA/LDD_om. 
The sequence and restriction sites of the oligonucleotides are given in Section 2.8 (list of 
primers). 
 
The PCR product was cloned into a pCR®TOPO2.1® vector (Invitrogen) and transformed into 
chemically competent E. coli Top10 cells. A colony was inoculated into 5ml of LB broth, 
followed by plasmid extraction according to the QIAprep Spin Miniprep kit (QIAGEN) protocol. 
The plasmid was sequenced using am ABI PRISM 3100 capillary sequencer (Applied 
Biosystems, USA) at 1st Base Pte Ltd. For sequencing inserts in the TOPO vector, the T7 forward 
and T7 reverse primers were used.  
 
The plasmid was then digested with the appropriate restriction enzymes as given in Section 2.8. 
The digested product was ligated into the corresponding restriction sites of pMind (Figure 2.3) 
and transformed into chemically competent E. coli Top10 cells. A colony was inoculated into 5 
ml of LB broth, followed by plasmid extraction according to the QIAprep Spin Miniprep kit 
(QIAGEN) protocol. Subsequently, the plasmid was transformed into electrocompetent M. 
smegmatis cells (see Section 2.3.4). For tetracycline induction of the pMind containing the gene 
of interests, previously described method (Blokpoel et al., 2005) was used. Cells were grown to 
mid-log phase (OD600nm ~ 0.5) in 7H9 medium containing selection antibiotics at 37°C. 
Tetracycline was added when appropriate. 
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Figure 2.3 Map of pMind plasmid taken from Blokpoel et al (2005). 
 
 
2.5.2 Dose-dependent tetracycline regulation of pMind_GFP, pMind_GFP_SsrA/LAA and 
pMind_GFP_SsrA/LDD in M. smegmatis 
M. smegmatis cells harboring pMind_GFP, pMind_GFP_SsrA/LAA and pMind_GFP_SsrA/LDD 
were grown to mid-log phase (OD600nm ~ 0.5). Doubling dilutions of tetracycline from 20 ngml-1 
to 1.25 ngml-1 were added to triplicate samples of each construct in 96-well clear bottom plate 
(Nunc™, Apogent, Denmark). At various time point (0, 2, 5, 7 and 24 hours), the cell density was 
measured by absorbance reading at OD600nm (SPECTRAmaxM2, Molecular Devices, USA). The 
cells were centrifuged at 3,000rpm for 5 minutes and the supernatant was discarded. 
Subsequently, the cells were resuspended in phosphate-buffered saline (PBS) and transferred to 
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96-well black bottom plate (Costar®, Corning Inc., USA). GFP fluorescence was measured using 
Safire2 (Tecan, USA) at 515 nm following excitation at 485 nm. M. smegmatis cells carrying 
pMind plasmid alone were used as negative control. 
 
 
2.5.3 Effect of compound X on the degradation of GFP-ssrA tag into M. smegmatis  
M. smegmatis cells harbouring pMind_GFP, pMind_GFP_SsrA/LAA and 
pMind_GFP_SsrA/LDD were grown to OD600nm ~ 0.2-0.4. The cultures were diluted with 7H9 
medium to OD600nm ~ 0.02. Various concentrations of Compound X (0 μM, 0.125 μM and 0.3 
μM) were added to the cells, followed by incubation at 37°C overnight. Tetracycline (20 ngml-1) 
was added to the cells and at different time points (0, 2, 4, 6, 8, 16 and 24 hours), cells from each 
condition was transferred to triplicate wells of 96-well clear bottom plate and the cell density was 
measured by absorbance reading at OD600nm. The cells were centrifuged at 3,000rpm for 5 
minutes and the supernatant was discarded. Subsequently, the cells were resuspended in 
phosphate-buffered saline and transferred to 96-well black bottom plate. GFP fluorescence was 
measured using Safire2 at 515 nm following excitation at 485 nm. 
 
2.6 In vitro proteolytic degradation of GFP carrying SsrA tag 
Purified GFP with or without the SsrA recognition tag (LAA or LDD) was used as a substrate in 
this in-vitro proteolytic assay. Degradation of GFP substrate (1 µM) by ClpC1 (1 µM) and ClpP1 
(1 µM) or ClpP2 (1 µM) or both was carried out in buffer containing 200 mM KCl, 50 mM Tris-
HCl pH7.5, 10 mM MgCl2, 10% glycerol and 1 mM DTT, with an ATP-regeneration system (5 
mM ATP, 16 mM creatine phosphate; Sigma , 6 µgml-1 creatine phosphokinase; Sigma). 
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Degradation of GFP was monitored by loss of fluorescence using Safire2 with excitation at 485 
nm and emission at 515 nm. 
 
 
2.7 Overexpression of M. tuberculosis ClpP1 and ClpP2 in M. smegmatis 
2.7.1. Construction of overexpressed mutants  
ClpP1 and clpP2 genes were overexpressed in M. smegmatis using tetracycline-inducible system 
pMind plasmid. Briefly, each gene was PCR-amplified using HotStar HiFidelity DNA 
Polymerase from M. tuberculosis (H37RV) genomic DNA using the given oligonucleotides, 
ClpP1_osm and ClpP2_osm, containing the respective restriction sites. The list of 
oligonucleotides and restriction sites used for each gene cloned is given in Section 2.8 (list of 
primers). The PCR product was cloned into a pCR®TOPO2.1® vector and transformed into 
chemically competent E. coli Top10 cells. A colony was inoculated into 5ml of LB broth, 
followed by plasmid extraction according to the QIAprep Spin Miniprep kit (QIAGEN) protocol. 
The plasmid was digested with the appropriate restriction enzymes. The digested product was 
ligated into the corresponding restriction sites of pMind (Figure 2.3) and transformed into 
chemically competent E. coli Top10 cells. A colony was inoculated into 5 ml of LB broth, 
followed by plasmid extraction according to the QIAprep Spin Miniprep kit (QIAGEN) protocol. 
Subsequently, the plasmid was transformed into electrocompetent M. smegmatis cells (see 
Section 2.3.4). For tetracycline induction of the pMind containing the gene of interests, 
previously described method (Blokpoel et al 2005) was used. Cells were grown to mid-log phase 
(OD600nm ~ 0.5) in 7H9 medium containing selection antibiotics at 37°C before addition of 
tetracycline (20 ng ml-1). 
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2.7.2 Western Blot analysis of overexpressed ClpP1 and ClpP2 strains 
Anti-ClpP1 and anti-ClpP2 antibodies (BioGenes, Germany) were raised in rabbits and the 
antisera were collected. 100 ml culture of M. smegmatis cells harbouring pMind-ClpP1 or pMind-
ClpP2 were grown in 7H9 medium containing 25 µgml-1 kanamycin and 50 µgml-1 hygromycin at 
37°C to reach OD600nm ~ 0.5. Tetracycline concentration of 20 ngml-1 was added to the culture to 
allow induction and incubation at 37°C was continued for another 5 hours. The cells were 
harvested by centrifugation at 3,000rpm for 15 minutes. The supernatant was discarded and the 
protein lysate was extracted as follow. The cell pellets were washed three times with ice-cold 
water containing 0.05% (v/v) Tween-80. The final pellet was resuspended in 500 µl of lysis 
buffer containing 50 mM Tris-HCl pH7.5, 5% glycerol, 1.5 mM MgCl2, 150 mM NaCl, 1 mM 
Na3VO4, 1 mM DTT, 1% NP40 and Protease Inhibitor Tablet. The cells were lysed by bead 
disruption in a ribolyser (Eppendorf, Germany) for three times with incubation on ice in-between 
intervals. The debris in the lysate was spun down and the supernatant removed. The protein 
concentration of each sample was estimated using the BCA Protein Assay Reagent (Thermo 
Fisher Scientific, USA). 10 µg of protein sample was loaded onto pre-cast NuPAGE® Novex® 
Bis-Tris Mini Gels 4-12% with NuPAGE® MES running buffer and gel electrophoresis was run 
at 200 Volts, 400 mA for 35 minutes. Gel was removed from pre-cast and ready for western blot 
transfer. 
 
Protein from the gel was electroblotted onto PVDF Transfer Membrane (Amersham Biosciences) 
at 120 Volts, 400 mA for 1 hour. The membrane was blocked overnight in blocking buffer 
consisting of 3% (w/v) Bovine Serum Albumin Fraction V in TBS (10 mM Tris-Cl pH7.5 and 
150 mM NaCl). The membrane was washed three times with TBS (20 mM Tris-Cl pH7.5 and 500 
mM NaCl) containing 0.05% (v/v) Tween-20 and 0.2%(v/v) Triton X-100 and one time with TBS 
with 0.05% (v/v) Tween-20 before incubation with primary antibody for 2 hours at room 
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temperature. The membrane was washed again as before prior to incubation with secondary 
antibody for 1 hour at room temperature. Rabbit anti-ClpP1 or rabbit anti-ClpP2 was used as the 
primary antibody, while goat anti-rabbit IgG (BIO-RAD) was used as secondary antibody. After 
washing, the membrane was incubated with 1-2 ml of Alkaline Phosphatase BCIP/NBT – Blue 
Liquid Substrate System for Membrane (Sigma, USA) until the expected bands appear. The 
membrane was then rinsed with dH2O to remove the detecting reagent. 
 
2.7.3 Cell and colony morphology of M. smegmatis overexpressing M. tuberculosis ClpP1 
and ClpP2 
M. smegmatis cells harbouring pMind-ClpP1 or pMind-ClpP2 were grown in 7H9 medium 
containing 25 µgml-1 kanamycin and 50 µgml-1 hygromycin at 37°C to reach OD600nm ~ 0.5. 
Tetracycline concentration of 20 ngml-1 was added to the culture to allow induction and 
incubation at 37°C was continued for another 5 hours. At the end of incubation, 100 µl of each 
culture was collected and placed on a microscope glass slide. The morphology of the bacilli was 
observed under microscope (Nikon ECLIPSE E400) at 1000X magnification. M. smegmatis 
carrying empty plasmid pMind was used as control. At the same time, some sample of cells was 
plated at different dilutions on Middlebrook 7H10 agar plates containing 20 ngml-1 tetracycline. 
The plates were incubated at 37°C for 2 days until colonies were formed. Colonies formed were 




2.8 Primers and strains used in this study 
On Table 2.2 and 2.3, we listed the primers and strains that we utilized in this study.  
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Table 2.2 List of primers used in this study. 
Purpose Primer Oligonucleotides (5'-3') Restriction sites
ClpC1 5' flanking (LEFT) forward 5'TAGGTACCAGTGGGACCTCTATCTGCGCG3'
reverse 5'ATTCTCGAGGCCTCTTCCTGAGCCAGGA3'














GFP-wt_prot forward 5'GGATCCAGTAAAGGAGAAGAACTTTTCAC3' BamHI
reverse 5'TATTAATTAATTATGCTTTGTATAGTTCATCCATGCCAT3' PacI
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Table 2.2 (continued) 
Purpose Primer Oligonucleotides (5'-3') Restriction sites














ClpP1_osm forward 5'TAGGATCCGTGAGCCAAGTGACTGACATG3' BamHI
reverse 5'TATTAATTAATCACTGTGCTTCTCCATTGAC3' PacI
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Table 2.3 List of strains used in this study. 
Strain or plasmid Description Reference
M. tuberculosis H37RV Laboratory strain (ATCC 25618) http://genolist.pasteur.fr/TubercuList/
M. bovis BCG Pasteur Attenuated laboratory strain http://genolist.pasteur.fr/BCGList/
M. smegmatis mc2155 Wild type strain http://cmr.jcvi.org/cgi-bin/CMR/GenomePage.cgi?org=gms
E. coli Top10 cloning host, chemical competent Invitrogen (USA)
E. coli BL(21)DE3 RP expression host, T7 promoter, cam R Stratagene (USA)
E. coli Tuner (DE3) expression host, T7 promoter Merck (USA)
pCR®TOPO2.1® cloning of PCR product, kan R , amp R , lacZ Invitrogen (USA)
pNAT745 entry vector in Gateway protein expression system, gent R Novartis in-house
pHisKan5 / pNAT80
Gateway destination vector, His-tag and solubility 
enhancing tag, kan R
Freuler et al (2008)
pTrxKan5 / pNAT82
Gateway destination vector, His-tag and solubility 
enhancing tag, kan R
Freuler et al (2008)
pMBPKan5 / pNAT83
Gateway destination vector, His-tag and solubility 
enhancing tag, kan R
Freuler et al (2008)
pUbiKan5 / pNAT84
Gateway destination vector, His-tag and solubility 
enhancing tag, kan R
Freuler et al (2008)
pRbxKan5 / pNAT85
Gateway destination vector, His-tag and solubility 
enhancing tag, kan R
Freuler et al (2008)
pNusKan5 / pNAT86
Gateway destination vector, His-tag and solubility 
enhancing tag, kan R
Freuler et al (2008)
pZZKan5 / pNAT1052
Gateway destination vector, His-tag and solubility 
enhancing tag, kan R
Freuler et al (2008)
pGGKan5 / pNAT1058
Gateway destination vector, His-tag and solubility 
enhancing tag, kan R
Freuler et al (2008)
pYUB854 or p854 cosmid vector containing allelic exchange substrates, for creation of deletion mutant Bardarov et al (2002)
p854/ClpC1 ClpC1 gene in pYUB854 This study
pGOAL17 marker gene P Ag85-lacZ-P hsp60 -sacB Parish and Stoker (2000)
ClpC1-sco ClpC1 single crossover strain This study
pMind mycobacterial shuttle plasmid, tet promoter, kan R,  hyg R Blokpoel et al (2005)
pMind-GFP_wt
wild type GFP gene downstream of tetRO in pMIND, 
kan R , hyg R
Srinivasa Rao - NITD, personal 
communication
pMind-GFP_SsrA/LAA
GFP with SsrA/LAA tag downstream of tetRO in pMIND, 
kan R , hyg R
This study
pMind-GFP_SsrA/LDD
GFP with SsrA/LDD tag downstream of tetRO in pMIND, 
kan R , hyg R
This study









camR: chloramphenicol resistance marker, kanR: kanamycin resistance marker, ampR: ampicillin resistance 
marker, gentR: gentamicin resistance marker, hygR: hygromycin resistance marker 
 








Chapter Three: Results 
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3.1 Antibacterial activity of Compound X 
Compound X was evaluated for its inhibitory activity against M. bovis BCG and M. smegmatis. 
The results were compared against that of M. tuberculosis (Table 1.3 and 1.4, NITD’s results, 
unpublished data). Similar results were obtained from the activity against M. bovis BCG and M. 
tuberculosis, with Compound X displaying greater inhibitory and bactericidal activity than 
streptomycin and comparable to moxifloxacin. Meanwhile, the MIC50 value of Compound X 




3.2 Essentiality of ClpC1 gene in M. bovis BCG 
To confirm the requirement of functional ClpC1 for Compound X, we next investigated the 
feasibility of generating a clpC1 deletion mutant in M. bovis BCG. This strain was selected based 
on M. tuberculosis ClpC1 and M. bovis BCG ClpC1 peptide sequences showing high degree of 
similarity with a percentage of identical amino acids of 100% (Supplementary data) and both 
strains have similar MIC50 values against Compound X of ~ 0.05 mg/L. 
 
A two-step allelic-exchange methodology (Parish and Stoker, 2000) was employed to generate 
clpC1 deletion mutants. As described by Parish and Stoker, a one –step strategy can be used to 
generate marked mutations, but in some cases the required mutants will not be obtained, for 
example if the gene is essential or the recombination frequency at that locus is low. As we are 
using a two-step process only one single crossing over transformant is required. Thus the reduced 
transformation efficiency of M. tuberculosis does not pose a problem (Parish and Stoker, 2000). 
A suicide plasmid, p854-ClpC1 (Figure 2.1) was electroporated into M. bovis BCG, and 
transformants were selected on hygromycin and X-Gal plates. Ten transformants were isolated 
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after electroporation. Unexpectedly, all colonies were white, suggesting that the lacZ gene was 
not being expressed in M. bovis BCG. However, we have confirmed by PCR using primers  that 
lie outside of the clpC1 inserts used in the mutagenesis that representative colonies were single 














Figure 3.1 PCR analyses of M. bovis BCG clpC1 single crossover (SCO) strain (BCG-sco) (A) 
Arrangement of genes in the M. tuberculosis chromosome, showing the regions used in the construction of 
clpC1 deletion mutant. White arrows PEG-PGRS59, lsr2 and lysS genes; black arrow clpC1 gene; grey box 
shows region replaced in clpC1 by hyg gene. (B) PCR of SCO strain. Lanes 1: DNA 1kb plus ladder, 2: 
PCR was carried out using primers ClpC1.1 and ClpC1.2, which produced a band of 1 kb from the deleted 
region of ClpC1, indicating that ClpC1 is intact in the SCO strain. 3: Amplification of Hygromycin cassette 
with primers Hyg1 and Hyg2 which produced a band of 0.5 kb, indicating that p854-ClpC1 suicide vector 
was integrated in the chromosome. 4 and 5: Mapping of SCO. PCR was carried out using primers ClpC1.3 
and Hyg3 and ClpC1.4 and Hyg4. ClpC1.3 lies within gene PE-PGRS59 and ClpC1.4 lies within gene lsr2, 
both outside the insert used in the clpC1 mutagenesis, while Hyg3 and Hyg4 lies within hygromycin 
cassette and allow the amplification of the hygromycin flanking region. Only amplification with ClpC1.4 
and Hyg4 produced a band of 1.4 kb, suggesting that SCO had taken place on the right side of clpC1.  Wild 
type M. bovis BCG did not amplify the region as this strain is not carrying the plasmid p854-ClpC1 (data 







Since the lacZ gene was not expressed in M. bovis BCG, we transformed p84-ClpC1 plasmid in 
M. tuberculosis. The hygR single crossing-over transformants obtained were blue on X-Gal plates, 
confirming that lacZ was being expressed in M. tuberculosis (it’s unclear why lacZ was only 
expressed in M. tuberculosis). As for BCG we have confirmed by PCR that single croos-over 
occurred in clpC1 gene. A single cross-over colony was streaked out and a loopful of cells 
resuspended in medium and plated onto sucrose X-Gal plates. After the second recombination 
event, the selection markers were eliminated (PCR analyses of lacZ gene shown that these 
colonies had loss the plasmid, data not shown) and 75 revertant (Sucr Hygr) colonies were 
screened by PCR. All were positive for chromosomal clpC1 suggesting that this gene is 
essential and cannot be deleted.  Experiment are in progress to demonstrate the 
essentially of clpC1 by cloining a copy of clpC1 gene into pMV262 vector. This 
construction is being introduced into the single-crossover M. tuberculosis clpC1 strain. 
The availability of a wild-type copy of the gene will enable the second crossing-over to take 
place.        
 
Therefore, we could not determine whether the presence of a functional clpC1 is a requirement 
for Compound X activity in M. tuberculosis and if its absence or inactivity is sufficient for 
Compound X resistance. This experiment is on-going at NITD. 
 
3.3 Sub-cloning and expression of ClpC1 
M. tuberculosis ClpC1 was purified using a novel Gateway-based vector system for protein 
expression in E. coli (Freuler et al., 2008). In this system the protein of interest is expressed with 
various N-terminal fusion tags in order to determine which of the tags leads to the highest level of 
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soluble protein. Figure 3.2 shows an SDS-PAGE with small scale purification to determine the 
destination vector that gives the highest yield of soluble ClpC1. Tags MBP (pNAT83), Ubi 
(pNAT84) and Nus (pNAT86) showed a higher amount of expressed and soluble protein. We 
selected construct 4 (pNAT84) for up-scaled expression and purification process. After cells lysis, 
the soluble fusion protein was bound to a His-trap column and washed extensively to remove 
nonspecific protein contamination. ClpC1 was then eluted after cleavage of the fusion protein and 
subsequent purification by size exclusion chromatography using Gel Filtration column. The 
expressed protein migrated as a 93kDa with the 13.8kDA-tag (Figure 3.3). According to Gel 
Filtration chromatography profile, ClpC1 eluted as a dimeric protein similar to that of other 
HSP100 proteins (Andersson et al., 2006; Beuron et al., 1998). 
 
 
pNAT80 pNAT82 pNAT83 pNAT84 pNAT85 pNAT86 pNAT1052 pNAT1058
Novex® Sharp 
Protein Standard Vector:
Construct: 1 2 3 4 5 6 7 8
S     I     E S     I     E S     I     E S     I     E S     I     E S     I     E S     I     E S     I     E
 
Figure 3.2 Small scale expression and purification of ClpC1. Different construct refers to different 





















Elution volume (ml)  
Figure 3.3 Gel Filtration profile of M. tuberculosis ClpC1 following cleavage of the Gateway tag. 
Arrows indicate the elution of standards with the respective molecular weights. Purified ClpC1 (93kDa) 
migrated as a dimer (186kDa) at elution volume 12.39ml. The Gateway tag migrated as 13.8kDa protein at 






3.4 ClpC1 Displays Basal ATPase activity  
M. tuberculosis ClpC1 was annotated at Pasteur Institute Tuberculist server as a probable 
ATP-dependent protease that interact with a ClpP-like protease involved in degradation 







   1 MFERFTDRAR RVVVLAQEEA RMLNHNYIGT EHILLGLIHE GEGVAAKSLE SLGISLEGVR    60 
   61 SQVEEIIGQG QQAPSGHIPF TPRAKKVLEL SLREALQLGH NYIGTEHILL GLIREGEGVA   120 
  121 AQVLVKLGAE LTRVRQQVIQ LLSGYQGKEA AEAGTGGRGG ESGSPSTSLV LDQFGRNLTA   180 
  181 AAMEGKLDPV IGREKEIERV MQVLSRRTKN NPVLIGEPGV GKTAVVEGLA QAIVHGEVPE   240 
  241 TLKDKQLYTL DLGSLVAGSR YRGDFEERLK KVLKEINTRG DIILFIDELH TLVGAGAAEG   300 
  301 AIDAASILKP KLARGELQTI GATTLDEYRK YIEKDAALER RFQPVQVGEP TVEHTIEILK   360 
  361 GLRDRYEAHH RVSITDAAMV AAATLADRYI NDRFLPDKAI DLIDEAGARM RIRRMTAPPD   420 
  421 LREFDEKIAE ARREKESAID AQDFEKAASL RDREKTLVAQ RAEREKQWRS GDLDVVAEVD   480 
  481 DEQIAEVLGN WTGIPVFKLT EAETTRLLRM EEELHKRIIG QEDAVKAVSK AIRRTRAGLK   540 
  541 DPKRPSGSFI FAGPSGVGKT ELSKALANFL FGDDDALIQI DMGEFHDRFT ASRLFGAPPG   600 
  601 YVGYEEGGQL TEKVRRKPFS VVLFDEIEKA HQEIYNSLLQ VLEDGRLTDG QGRTVDFKNT   660 
  661 VLIFTSNLGT SDISKPVGLG FSKGGGENDY ERMKQKVNDE LKKHFRPEFL NRIDDIIVFH   720 
  721 QLTREEIIRM VDLMISRVAG QLKSKDMALV LTDAAKALLA KRGFDPVLGA RPLRRTIQRE   780 
  781 IEDQLSEKIL FEEVGPGQVV TVDVDNWDGE GPGEDAVFTF TGTRKPPAEP DLAKAGAHSA   840 
      841 GGPEPAAR 
 
 
Figure 3.4 The M. tuberculosis ClpC1 ATPase. The ClpC1 contain two nucleotide binding domains 
(AAA-, AAA-2) and the length of the spacing between those domains, as well the presence of specific 
signature sequences (not indicate in the figure), form the basis for the subfamily classification for Clp 
ATPases. Functional domains include the P domain which is required for binding ClpP and the N1 
(highlighted in blue) and N2 (highlighted in yellow) domains proposed to be involved in protein binding. In 
addition, a domain (UVR, highlighted in green) resembling the interaction domain between the nucleotide 





To determine whether ClpC1 has basal ATP activity, we used BIOMOL GREEN™ Reagent that 
measures the release of free inorganic phosphate when ATP is hydrolyzed to ADP. M. 
tuberculosis ClpC1 exhibited increasing ATPase activity with increasing ATP concentration 
(Figure 3.5). KM and kcat for the reaction are 0.78mM and 2.55 min-1, with a Vmax of 1.27 µMmin-
1. The activity was derived from the 2-hour measurement, which is within the linear range of the 
assay (Figure 3.6). 
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Figure 3.5 M. tuberculosis ClpC1 ATPase activity. ATPase activity was assayed with 0.5µM of ClpC1 at 
room temperature in a mixture containing various concentrations of ATP. ATPase activities were measured 
spectrophotometrically after 2 hours by the release of inorganic phosphate. (KM =0.78mM, kcat = 2.55 min-1, 
















Figure 3.6 Time course of M. tuberculosis ClpC1 ATPase activity. The measurement was performed at 
different time points over 4 hours. Up to ATP concentration of 0.5mM, the ClpC1 ATPase activity is linear 
with time, following Michaelis-Menten kinetics. At ATP concentration of 0.75mM and above, the activity 
is linear only up to 2 hours, beyond which the enzyme saturation is reached and Michaelis Menten kinetics 
is no longer applicable.    
 















































3.5 Effect of Compound X on the ATPase activity of ClpC1 
Having established that, as predicted from the primary structure, recombinant M. tuberculosis 
ClpC1 functioned like an ATPase, we investigated the effect of Compound X on the ATPase 
activity of ClpC1. Interestingly, Compound X stimulated the inherent ATPase activity of ClpC1 
(Figure 3.7). In the presence of 1 µM of Compound X, we observed a 3.4-fold reduction in the KM 
value of the reaction from 0.78 mM to 0.23 mM and an apparent increase in the turnover rate 
from 3.26 mM-1min-1 to 10.40 mM-1min-1, while the kcat and Vmax values remained relatively 
constant at 2.44 min-1 and 1.22 µMmin-1, respectively. This reduction in KM value suggests the 
potential role of Compound X as an allosteric activator.  





































Figure 3.7 The effect of Compound X (1µM) on the ATPase activity of M. tuberculosis ClpC1. ATPase 
activity was assayed with 0.5µM of ClpC1 at room temperature in a mixture containing various 
concentrations of ATP, in absence (---) or presence (___) of Compound X. ATPase activities were measured 
spectrophotometrically after 2 hours by the release of inorganic phosphate. In the presence of Compound 
X, KM =0.23 mM, kcat = 2.44 min-1, Vmax of 1.22 µMmin-1. Compound X decreased the KM value by 3.4-fold 
from 0.78 mM to 0.23 mM and increased the turnover rate from 3.26 mM-1min-1 to 10.40 mM-1min-1.    
 
 Compound X  
  - +   
Vmax 1.27 1.22 µM min-1 
Km 0.78 0.23 mM 
Enzyme conc 0.50 0.50 µM  
Kcat 2.55 2.44 min-1 
Turn over rate (Kcat/Km) 3.26 10.40 mM-1 min-1 
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Next, we tested the effect of increasing concentration of Compound X on the ClpC1 ATPase 
activity. We chose the ATP concentration of 0.3mM based on the Km value of the basal ATPase 
activity of ClpC1 and the assay was performed over 4 hours. These conditions fall within the 
linear range of the assay, where the Michaelis-Menten kinetics applies (Figure 3.6). We found 
that Compound X increases the ATPase activity of ClpC1 in a dose-dependent manner (Figure 
3.8). At high concentration of Compound X 100µM, we encountered solubility issue which 
accounts for the reduction in the stimulating effect. In addition, Compound X exhibited no 
ATPase stimulating effect on ClpX, demonstrating the specificity of the interaction of Compound 




































Figure 3.8 ClpC1 ATPase activity upon addition of Compound X.  ATPase activity was assayed with 
0.5µM of ClpC1 and different concentration of compound X at room temperature. ATPase activities were 
measured after 4 hours spectrophotometrically by the release of inorganic phosphate. Basal ClpC1 ATPase 





Subsequently, to determine if the ClpC1 ATPase stimulating activity can be correlated with the 
whole cell biological activity, we conducted similar ATPase assay using five different analogues 
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of Compound X. These compounds are derivatives of Compound X with similar structural 
scaffold, but exhibited varying MIC50 on M. tuberculosis. (Table 3.1). Interestingly, Compound X 
and Compound W which showed high anti-mycobacterial activity in vivo showed high ClpC1 
ATPase stimulating activity (Figure 3.9). By contrast, Compound Y and Compound Z which 
showed poor anti-mycobacterial activity showed weak ClpC1 ATPase stimulating activity in-
vitro (Figure 3.9). The correlation between in vitro enzyme stimulating activity and whole-cell 
biological activity provides support for the designed mechanism of action but need to be 
confirmed with more analogues of Compound X. We next asked how Compound X causes 


















































Figure 3.9 ClpC1 ATPase activity upon addition of Compound X and its analogues.  ATPase activity 
was assayed with 0.5µM of ClpC1 and different concentration of compounds at room temperature. ATPase 
activities were measured spectrophotometrically by the release of inorganic phosphate. Basal ClpC1 
ATPase level subtracted.  
 
 
Table 3.1 ClpC1 ATPase stimulating activity of different analogues of Compound X and its MIC50 values 




Compounds  M. tuberculosis 
Compound X 0.55 0.05  
Compound W 0.85 0.005 
Compound Z 0.40 (increase is negligible) No activity 




3.6 Compound X confer increased peptidase activity to ClpP via ClpC1  
The function of the ATPase is to carry proteins to ClpP, to unfold them in an ATP- consuming 
process and to thread them into the tiny entrance pore of the ClpP core. As Compound X had only 
a minor effect on the ATPase activity of native ClpC1, we hypothesized that the drug must 
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bestow novel activation properties to ClpC1 that result in activation of ClpP peptidases activity. 
As mentioned in Section 1.3.2, ClpP alone has an inherent activity to rapidly cleave short 
peptides and longer unstructured polypeptides. To degrade larger peptides and proteins, it 
requires an association with the ATPase to drive the proteolysis. We therefore investigated 
whether ClpC1 enhance the proteolytic capabilities of ClpP to degrade a whole protein in the 
presence of compound X.  
 
However, M. tuberculosis contains structural genes coding for two proteolytic ClpP proteases 
ClpP1 and ClpP2. Therefore, we first probed the M. tuberculosis ClpP1 and ClpP2 inherent 
peptidase activity on a fluorogenic substrate N-Succinyl-Leucine-Tyrosine-7-Amino-4-
Methylcoumarin (AMC), which was previously described as a model substrate for E. coli ClpP 
(Thompson et al., 1994). In this assay, fluorogenic AMC is quenched by short peptides, N-Suc-
Leu-Tyr, to give N-Suc-Leu-Tyr-AMC which is non-fluorogenic. Upon cleavage of a peptide 
bond, the AMC is released and fluorescence measurement can be made to quantify the activity of 






N – Succinyl – Leucine – Tyrosine 







Figure 3.10 Schematic diagram of hydrolysis of the peptide bond in N-Suc-Leu-Tyr-AMC by a peptidase, 
releasing fluorescent AMC. 
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M. tuberculosis ClpP1 and ClpP2 were cloned and purified using a novel Gateway-based vector 
system for protein expression in E. coli, as previously described for ClpC1 (See Section 3.5). 
Purified ClpP1 was inactive in peptide hydrolysis (Figure 3.11, white bars), consistent with 
previous finding (Ingvarsson et al., 2007). However, purified ClpP2 shows high peptidase activity 
that was dose-dependent up to 10 µM (Figure 3.11, grey bars). Furthermore, there was no 
















































Figure 3.11 Hydrolysis of the fluorogenic peptide N-succinyl-Leu-Tyr-amidomethylcoumarin (AMC) 
by M. tuberculosis ClpP1 and ClpP2. Fluorescence of released AMC was used  to determine the 
peptidase activity of different concentrations of ClpP1 (white bars), ClpP2 (grey bars) and combination of 





Having determined the activity of ClpP1 and ClpP2 peptidases, we next examined the 
degradation of casein mediated by ClpC1P proteolytic complex. Casein is a mostly unstructured 
protein (Herskovits, 1966) widely used as model protein substrate for studies of the Clp protease 
complex. It is readily degraded by purified E.coli ClpP in the presence of a Clp-ATPase, but 
remains intact in the presence of ClpP alone. In agreement with this, we found that purified M. 
tuberculosis ClpP1 or ClpP2 were not able to degrade -casein (Figure 3.12). But in the presence 
of ClpC1, only ClpP2 degraded casein (Figure 3.13). Furthermore, when all the three components 
namely ClpC1, ClpP1, and ClpP2 were present, the degradation of β-casein was even more 
efficient (Figure 3.13).  
 
Figure 3.12 Time course of β-casein degradation by M. tuberculosis ClpC1, ClpP1 or ClpP2. Proteins 
with ATP regenerating system were incubated with β-casein  and samples were taken at indicated time 






Figure 3.13 Time course of β-casein degradation by combination of M. tuberculosis ClpC1, ClpP1 or 
ClpP2. Proteins combination with ATP regenerating system were incubated with β-casein and samples 
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Next, we investigated the effect of Compound X on the Clp degradation of β-casein. There were 
no detectable changes in the combination of ClpC1 and ClpP1; the protein band corresponding to 
β-casein remained visibly intact (Figure 3.14). In the reaction containing ClpC1 and ClpP2, 
Compound X increased the degradation efficiency of β-casein (Figure 3.14). The effect of 
Compound X was even more prominent in the reaction containing ClpC1, ClpP1 and ClpP2, with 
the band starting to diminish at earlier time point (Figure 3.14). Thus, Compound X binds to 
ClpC1 and increases the proteolytic efficiency of ClpC1P complex. Additionally, the increased 
proteolytic degradation that was observed is confined within the substrate used, β-casein, while 
the other enzymes used as part of the in vitro system namely the Clp complex and the casein 
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Figure 3.14 Time course of β-casein degradation by combination of M. tuberculosis ClpC1, ClpP1 or 
ClpP2 in the presence of Compound X. Proteins combination with ATP regenerating system were 
incubated with β-casein and 5 µM of compound X. Samples were taken at indicated time points and 




3.7 Compound X confers degradation of GFP-ssrA in vivo    
The degradation of GFP-ssrA by ClpCP and ClpXP has been studied extensively in vivo, and the 
fluorescence assays by monitoring the GFP-ssrA levels following overproduction from plasmids 
in vivo have been described (Kim et al., 2000; Weber-Ban et al., 1999). To develop a sensitive 
assay for intracellular degradation where we can measure the activity of the Compound X, we 
constructed M. smegmatis strains expressing genes encoding either for GFP-ssrA or GFP. We 
created GFP-SsrA/DD, in which the terminal alanine residues are replaced with aspartate residues 
because it has lower affinity for ClpX and ClpA and is less efficiently degraded by ClpAP or 
ClpXP (Levchenko et al., 1997). We anticipated that such construction in the presence of 
Compound X should be rapidly degraded by ClpC1P complex. A tetracycline inducible promoter 
was used to drive transcription of GFP-ssrA or GFP (Blokpoel et al., 2005). M. smegmatis was 
chosen to be the expression host due to its fast-growing nature and genome homology to M. 
tuberculosis as well as M. bovis BCG. Sequence alignments of the genes involved in the 
proteolytic complex showed considerable similarity between the M. tuberculosis and M. 






























































Figure 3.15 Schematic diagram for ClpC1P degradation of GFP-srrA in M. smegmatis. (A) GFP-
ssrA/LAA tag is recognized by ClpC1P complex and efficiently degraded, thus low fluorescence level of 
GFP being detected. (B) GFP-ssrA/LDD is not fully recognized by ClpC1P complex and less efficiently 
degraded, leading to intermediate fluorescence level of GFP. (C) Untagged GFP is not recognized by the 





The GFP-reporter vectors were individually transformed into M. smegmatis and expression of gfp 
variants were induced by adding doubling dilutions of tetracycline from 20 to 1.25 ng ml-1. 
Quantification of GFP activities after 7 hours of cultivation demonstrated that concentration of 20 
ngml-1 tetracycline gave maximal GFP activities (Figure 3.16). This concentration is 10-fold 
below the MIC of tetracycline (data not shown). When GFP-SsrA/LAA was induced in M. 
smegmatis, the fluorescence of the cells was similar to control cells with no reporter protein, 
regardless of the tetracycline concentration added (Figure 3.16; ▼=GFP-SsrA/LAA, ■=control). 
Cells expressing GFP-SsrA/LDD displayed fluorescence but the average fluorescence was 
significantly higher in cells expressing untagged GFP (Figure 3.16; ♦=GFP-SsrA/LDD, 
▲=untagged GFP). These results are consistent with the expectation that GFP-SsrA/LAA should 

















































































































































































Figure 3.16 Tetracycline-induced GFP expression of M. smegmatis carrying pMind –GFP with and without the SsrA recognition tag. GFP 
fluorescence was measured at different time points. Tc (x-axis): concentration of tetracycline used in ng/mL, Normalized RFU (y-axis): RFU/OD of 
tetracycline-induced culture subtract RFU/OD of uninduced culture. pMind: empty vector, GFP wt: pMind-GFP, LAA: pMind-GFP-SsrA/LAA, 
LDD: pMind-GFP-SsrA/LDD. Cell viability was measured at each time point with absorbance reading at 600nm. No cell killing due to tetracyline 
was observed (data not shown). 
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Next, we performed an experiment to determine whether Compound X stimulate the degradation 
of GFP-SsrA tagged proteins expressed in M. smegmatis. We added sub-lethal concentrations of 
Compound X (0.125µM or 0.3µM) into M. smegmatis cultures overnight, prior to induce GFP-
SsrA expression with 20 ng ml-1 tetracycline. In M. smegmatis GFP-SsrA/LAA fluorescence was 
undetectable under all growth conditions tested. This result was expected as GFP-SsrA/LAA is 
efficiently degraded in absence of Compound X (Figure 3.16). Interestingly, Compound X 
enhance the degradation of GFP-SsrA/LDD and untagged GFP. At 16 hour following induction, 
in GFP-SsrA/LDD the fluorescence of the cells was reduced 3.5-fold with 0.125µM and 
approximately 5-fold with 0.3µM of Compound X, respectively (Figure 3.17). In untagged GFP, 
the fluorescence was reduced by 1.7-fold with 0.125µM of Compound X and by 3-fold with 
0.3µM of Compound X (Figure 3.17). The cell density at each time point was also measured to 
ensure that any reduction in fluorescence observed is not due to cell killing. Indeed, absorbance 
reading at 600nm showed that cells continue to grow up to 16 hour following induction by 
tetracycline for both M. smegmatis carrying pMind-GFP_SsrA/LDD (Figure 3.17) and M. 
smegmatis carrying pMind-GFP_wt (Figure 3.17). Our results suggest that Compound X in vivo 
might activate Clp ATPase in a way that the protein lost the substrate discrimination that promote 
degradation of proteins without SsrA tag.   
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Figure 3.17. Effect of Compound X in the degradation of GFP-ssrA/LDD and untagged GFP in M. 
smegmatis. (A) Degradation of GFP-ssrA/LDD monitored by fluorescence. (B) Cell density of M. 
smegmatis expressing GFP-ssrA/LDD measured by absorbance reading at OD600nm. (C) Degradation of 
untagged GFP monitored by fluorescence. (D) Cell density of M. smegmatis producing untagged GFP 
measured by absorbance reading at OD600nm 
 
 
3.8 In vitro proteolysis of GFP-SsrA by M. tuberculosis ClpC1-ClpP complex 
As the preceding experiment suggests that Compound X might induce loss of substrate 
recognition by ClpC1 ATPase, we hypothesize that Compound X must induce the degradation of 
untagged GFP and GFP-SsrA/LDD, but enhance the degradation of GFP-SsrA/LAA in vitro. We 
therefore, investigated this possible effect in a in vitro assay using GFP-SsrA. Untagged GFP, 
GFP-SsrA/LAA or GFP-SsrA/LDD was expressed and purified using the Gateway system as 
previously described for ClpC1 in Section 3.5. Unfortunately, we did not witness degradation of 
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any of the GFP variants. The reason for the failure in observing the degradation of the GFP 
variants is unknown, but possibly due to unsuccessful denaturation or rapid refolding of GFP 
following unfolding by ClpC1. Due to time constraint, we did not pursue the experiment further 
to optimize the conditions.  
 
3.9 Overexpression of ClpP1 and ClpP2 
Previous studies have shown that overexpression of clpP1 and clpP2 accelerate aerial mycelium 
formation in S. lividans, S. albus and S. coelicolor (de Crecy-Lagard et al., 1999). To gain more 
insights into the role of ClpP in M. tuberculosis, we overexpressed the genes clpP1 and clpP2. 
We were interested to find out if the findings mentioned above can be extrapolated to ClpP in M. 
tuberculosis. ClpP1 or clpP2 gene was PCR-amplified from M. tuberculosis H37RV and cloned 
into tetracycline-inducible vector pMind (Blokpoel et al., 2005). The cloned plasmid was 
transformed into M. smegmatis. Overexpression of the gene was carried out by adding 20 ngml-1 
of tetracycline. To check that the gene was properly overexpressed, antibody against the gene was 
raised in rabbit. Western blot analysis confirmed the overexpression as shown by the thick band 
corresponding to the size of ClpP2 from lysate of tetracycline-induced M. smegmatis carrying 
pMind-ClpP2 (Figure 3.18 A). Meanwhile, the lysates of M. smegmatis carrying pMind vector 
alone and M. smegmatis carrying pMind-ClpP1 produced very faint bands corresponding to the 
size of ClpP2, indicating that the basal expression of clpP2 is relatively low. However, in the 
latter two samples, we detected bands corresponding to the size of ClpP1. This shows that the 
anti-ClpP2 antibody was not specific and could cross-react with ClpP1. Furthermore, the lane 
corresponding to purified ClpP2 showed a few bands of other sizes. One of the bands of size 
60kDa suggested uncleaved ClpP2, while the band of size 40kDa suggested His-tag that was not 




Western blots analysis also confirmed the overexpression of clpP1 as shown by the thick band at 
the size of ClpP1 from lysate of tetracycline-induced M. smegmatis carrying pMind-ClpP1 
(Figure 3.18 B). Such band was relatively thinner from the lysates of M. smegmatis carrying 
pMind alone as well as pMind-ClpP2. This confirms that overexpression only occurred when the 
pMind vector carried the gene of interest and that tetracycline was added to induce 
overexpression of the gene product. The anti-ClpP1 antibody was more specific as such that it did 
not show any other band, for instance one that correspond to ClpP2. Nonetheless, western blot 
analysis using purified ClpP1 also showed two other bands of size 60kDa and 40kDa, possibly 













Figure 3.18 Western blot analysis of clpP1 and clpP2 overexpression. (A) Western blot using antibody 
raised against ClpP2. Lanes correspond to (from left to right): purified ClpP2, lysate of tetracycline-
induced M. smegmatis carrying pMind-ClpP2, lysate of tetracycline-induced M. smegmatis carrying 
pMind-ClpP1, lysate of M. smegmatis carrying pMind vector alone. (B) Western blot using antibody raised 
against ClpP1. Lanes correspond to (from left to right): purified ClpP1, lysate of tetracycline-induced M. 
smegmatis carrying pMind-ClpP2, lysate of tetracycline-induced M. smegmatis carrying pMind-ClpP1, 
lysate of M. smegmatis carrying pMind vector alone. (C) SDS-PAGE of protein lysates from the different 
strains of M. smegmatis (equal loading) and purified proteins ClpP1 and ClpP2. Bio-Rad Precission Plus 






In order to investigate the effect of overexpression of clpP1 or clpP2, we looked into any possible 
morphological changes that could be brought about by this genetic manipulation. Overexpression 
of clpP1 or clpP2 did not lead to any morphological changes in the bacilli formation and neither 
did it cause any changes in colony formation as compared to the wild type M. smegmatis carrying 
pMind vector alone (Figure 3.19). Since clpP1 and clpP2 belong to the same operon (Figure 








Figure 3.19 Cell and colony morphology of M. smegmatis mutants carrying: empty plasmid pMind (A), 






Figure 3.20 Genomic region of M. tuberculosis and M. smegmatis clpP1 (black arrow) and M. tuberculosis 
and M. smegmatis clpP2 (red arrow).  
 








Chapter Four: Discussion 
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New antibiotics with new mechanism of actions are urgently needed to keep pace with the 
increasing incidence of multidrug resistant tuberculosis. The natural product Compound X 
represents a new class of molecules that has excellent activity against both M. bovis BCG and M. 
tuberculosis. This class of drug has real potential to be developed as a treatment of mycobacterial 
infections. In addition, the apparent low frequency of colonies resistant to Compound X indicates 
that the frequency of selection of M. tuberculosis strain resistant to drugs of this class may be less 
than that observed with rifampicin or isoniazid. Such potential anti-mycobacterial compound 
instigated the search for its target in vivo. The group led by Schmitt et al (NIBR) carried out the 
pull down experiment whereby the compound is immobilized onto a column and the protein 
lysate from M. bovis BCG was passed through the column (See Section 1.4.3). The crude 
experiment found a binding of ClpC1 an ATPase of the Clp/Hsp100 family, which assembles as a 
homohexameric on one or both sides of ClpP peptidase and is strictly required for proteolytic 
processing. The function of the ATPase is to carry proteins to ClpP, to unfold them in an ATP 
consuming process and to thread them into the tiny entrance pores of ClpP core.  
 
Our experiments show that Compound X specifically binds to ClpC1 and stimulates its ATPase 
activity. Interestingly, Compound X increases the ATPase activity of ClpC1 above the basal 
level. The extent of this stimulation results in the improvement of casein degradation (which we 
chose as an exemplary protein substrate) by the ClpP1 and ClpP2 proteolytic enzymes.  
 
Neither ClpP1 or ClpP2 alone nor combination of both yielded any casein degradation. 
Degradation indeed proceeded when ClpC1 was added into the reaction and was faster in the 
presence of Compound X without the need of other chaperones or adaptor protein like MecA 




This notion is further supported by our findings in the cell-based assay. Here, we took advantage 
of a reporter gene GFP to enable us to observe the effect of Compound X on the proteolytic 
degradation inside the bacteria. Compound X increased the degradation of GFP with the mutated 
tag SsrA/LDD that was previously partially degraded. The presence of Compound X also 
accounted for degradation of GFP without any tag. These data show that Compound X increases 
degradation of proteins by relaxing the control system of recognition tagging. 
 
Nonetheless, it is noteworthy to keep in mind that cell-based assay involves many other key 
players inside the cell. One may argue that the effect exerted by Compound X may not be solely 
due to Clp proteosome complex or even may be due to completely other mechanism. Future 
studies with clpC1 deletion mutant will show whether other target contribute to the observed 
phenotype.  
 
We postulated that the modulation of ClpC1 ATPase activity will dysregulate ClpP1 and/or 
ClpP2 proteosome, leading to adverse physiological effect on bacterial cell. To establish such 
correlation, we attempted to overexpress clpP1 or clpP2 in M. smegmatis. Studies have shown 
that disruption or overexpression of clpP1 and/or clpP2 genes in several bacterial species produce 
conspicuous morphological changes. Overexpression of clpP1 and clpP2 accelerates aerial 
mycelium formation in S. lividans, S. albus and S. coelicolor (de Crecy-Lagard et al., 1999). In 
our study, we did not observe any visible morphological changes upon overexpression of these 
genes. However, lack of visible changes does not rule out the possibility of other physiological 
manifestations. Such manifestations could be in the form of changes in the differentiation 
process, consumption of substrate, production of metabolites or response towards stress. Due to 
time constraints, unfortunately these were not fully explored. In addition, overexpression of the 
gene does not necessarily translate to a dysregulation of function although it can serve as a gross 
analysis at the level of genetic manipulation. Furthermore, future investigations could also be 
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directed towards exploring the possible synergistic effect of overexpressing ClpP1/ClpP2 with the 
activity of Compound X and thus increasing protein degradation. 
 
Here, we would also like to take the chance to address our failure to develop the in vitro 
degradation system with GFP carrying the SsrA tag. We speculate that the unfolding attempt of 
the GFP was unsuccessful or that upon unfolding by ClpC1, the refolding of GFP was very rapid 
that most of the unfolded GFP got refolded back instead of being captured by ClpP and being 
degraded. Unfolding of a stable protein molecule by Clp ATPase is a very infrequent event, 
consuming large amount of ATP before denaturation is successful (Kenniston et al., 2003). 
Furthermore, the initial step of GFP denaturation produces a partially unfolded intermediate that 
refolds quickly, escaping degradation unless it is captured by fast translocation to ClpP (Martin et 
al., 2008). As for β-casein, it bears a disorganized structure that is usually a characteristic of a 
denatured protein (Herskovits, 1966). This structure of casein is likely to require less energy 
consumption during the denaturation process and thus higher probability of getting unfolded, 
translocated and degraded.  
 
How does Compound X stimulate the ATPase activity of ClpC1 and how does this correlate to 
the improved degradation of ClpP proteosome and finally how does it lead to cell death? There 
are several hypotheses that we propose on how Compound X stimulates the ATPase activity of 
ClpC1. Firstly, the stimulation profile upon addition of Compound X reduced the Km value by 
~3.4-fold and this profile fits into the profile of an allosteric activator. Such allosteric activator 
generally increases the binding affinity of the enzyme for its substrates. In addition, an allosteric 
site is located on a distinct site from the active site. Henceforth, binding of Compound X to an 
allosteric site could alter the conformation of ClpC1 in such a way that the ATPase binding site 
becomes more active. The altered conformation could lead to a better or tighter binding of ATP to 
the ATPase binding site, hence an increase in the ATP hydrolysis rate. At the same time, there 
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could be an accompanied improvement in binding affinity to the other substrate targeted for 
unfolding and translocation to the ClpP proteosome for degradation. This altered conformation 
could also interfere with the substrate recognition of protein tagged for degradation.  
 
The mechanism of substrate recognition is not widely understood. One possibility is that ‘correct’ 
tag could fit nicely into the binding pocket of ClpC1 while those without tag or the ‘incorrect’ tag 
does not provide a right fit. Altering conformation of ClpC1 could alter the binding pocket of 
substrate such that more substrate even without the right tag or no tag at all could fit nicely into 
the pocket. If this hypothesis holds, more proteins will be ‘recognized’ by ClpC1 and 
subsequently unfolded and translocated to the Clp proteosome for degradation. Henceforth, 
ClpC1 selectivity for substrate would be compromised, leading to uncontrolled degradation of 
proteins inside the cell. Degradation of proteins that hold key essential functions inside the cell 
will eventually lead to cell death.  
 
Another hypothesis that we propose would involve the functional equilibrium of the enzyme 
ClpC1. Literature reviews conclude the existence of hexameric ClpC as the functionally active 
conformation and that formation of hexamer is promoted upon addition of ATP (Kar et al., 2008). 
In our study, Gel Filtration analysis during the purification of ClpC1 in the absence of ATP 
revealed a dimeric state of the enzyme. The ATPase assay of ClpC1 showed an increase in 
ATPase activity upon addition of ATP as a substrate, in a substrate concentration dependent 
manner. The mechanism in which ClpC1 forms a hexamer has never been fully elucidated. The 
formation of hexameric state does not rule out the presence of the dimmeric or other oligomeric 
state of the enzyme. These states may exist in equilibrium, depending on the factors that drive the 
formation of an oligomer, for instance addition of ATP. We hypothesize that Compound X 
functions as a drive towards formation of a particular oligomeric state, which is more biologically 
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and functionally active. The increase in the number of biologically active conformation of ClpC1 
would result in a higher churn out rate of ATP and other substrate of ClpC1.  
 
Another area for future work is the overexpression of the gene coding for the ATPase subunit 
clpC1. Overproduction of clpX accelerates actinorhodin production in S. coelicolor and activates 
its production in S. lividans (de Crecy-Lagard et al., 1999). It is pragmatic to look at the effect of 
manipulating the clpC1 gene through overexpression – whether it will cause morphological or 
physiological changes to the cell or up/down regulation of other genes. 
 
A closer look at the activity of ClpP homologues discloses an interesting finding. Unlike ClpP2, 
ClpP1 did not exhibit peptidase activity even when put in combination with ClpP2. This data is 
consistent with previous findings by Ingvarsson et al. (2007). The author suggested the 
processing requirement of ClpP1. In S. coelicolor, the presence of ClpP2 is needed to obtain a 
processed ClpP1 and vice versa (Viala and Mazodier, 2002). However, this is not reflected in our 
study whereby ClpP2 does not require processing to be active. Furthermore, in the presence of 
ClpC1, the combination of both displayed a synergistic proteolytic activity towards β-casein. In 
the presence of ClpC1, ClpP2 alone was able to hydrolyze β-casein, albeit at a lower efficiency 
than when in combination with ClpP1. These observations seem to suggest that ClpC1 plays a 
role in the activation of ClpP1.   
 
Last but not least, ATP is known to have physiological significance for the survival of the cell 
such that depletion of it may lead to cell death (Gordon et al., 1986). At the same time, protein 
degradation by AAA+ protease is very costly, often using as much or even more energy that was 
expected for the synthesis of the protein (Sauer et al., 2004). If Compound X acts to stimulate the 
ATPase activity by increasing the hydrolysis of ATP, there could be a high intracellular depletion 
of ATP that might lead to cell death. One challenge in exploring this phenomenon is the 
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measurement of ATP level as low ATP level can also be interpreted as non-viable cells having 
reduced metabolism, thus making it difficult to determine true consumption of ATP by ClpC1.  
Future perspectives 
There have been several models of Clp proteolytic machinery, for instance one derived from H. 
pylori and E. coli (Kim and Kim, 2003; Thompson et al., 2004). Crystal structures for M. 
tuberculosis ClpP1 is already available, but none for ClpP2 and ClpC1. It will be insightful to 
explore how these proteins interact, especially with the presence of multiple isoforms. As 
suggested by Viala and Mazodier (2002) and Yu and Houry (2007), the two ClpP isoforms could 
form either homooligomer or heterooligomer, depending on which is the predominant 
physiological assembly. Furthermore, a previous study by Singh et al. (2006) showed protein 
interaction between ClpC1 and ClpP2, but such interaction was not observed between ClpC1 and 
ClpP1 or ClpP1 and ClpP2. Given these information, it is intriguing to figure out how they 
interact and at the same time how certain compound such as Compound X interacts with the 
whole complex. Crystal structures will be one viable option in elucidating their interactions.  
 
Flynn et al (2003) already showed that numerous metabolic enzymes appear to be potential 
substrates of ClpXP in E. coli (Table 1.2). One could easily envision that the loss of regulated 
proteolysis of these enzymes could alter the biochemical profile of a bacterium, changing its 
ability to survive and grow in a host. Proteomics analysis such as a 2-D gel electrophoresis and 
substrate trap experiments could be a starting point to examine this possibility in M. tuberculosis 
in the presence or absence of Compound X. 
 
Finally, an investigation on the effect of Compound X on a clpC1 deletion mutant model will 
allow a better understanding of the mechanism of action of Compound X. However, M. 
tuberculosis clpC1 was predicted to be essential (Ribeiro-Guimaraes and Pessolani, 2007). In this 
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regard, our findings on single crossover mutants still need to be confirmed with proper 
complementation of an extra copy of the gene. Nonetheless, if the gene is indeed essential, one 
possibility is to look for another model with close homology to M. tuberculosis clpC1. One such 
model is a clpC1 deletion mutant in Corynebacterium glutamicum that has been previously 
constructed (Engels et al., 2004). C. glutamicum shares ~80% protein similarity to M. 
tuberculosis. Hence, one possibility for future investigation is testing the effect of Compound X 
on clpC1 knockout strain of C. glutamicum. 
 








Chapter Five: Conclusion 
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In conclusion, the identification of ClpC1 as a 'target' for antibacterial compounds broadens our 
perspective of how to kill mycobacteria. Virtually all clinically useful antibacterial compounds 
inhibit essential bacterial functions—but Compounds X hyperactivates an essential function, 
inducing widespread protein degradation. Brötz-Oesterhelt et al (2005) already shows that a class 
of molecules, acyldepsipeptides acts by removing the stringent controls on a bacterial protease, 
unleashing the enzyme to degrade cellular proteins in an unregulated manner. Thus, targeting 
proteases and associated factors already shows promise for the development of new antimicrobial 
therapies. Finally, the results of this study will allow greater possibilities in chemical 
modification of the candidate compound thus leading to a better PK profile that enables this 
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Supplementary Data 
 
Supplementary data 1 
Sequence alignment of ClpC1 homologues corresponding to the Tuberculist entry for M. tuberculosis 
(Rv3596c), M. bovis BCG (Mb3629c) and the TIGR entry for M. smegmatis (6091 MC2) by CLUSTAL 
2.0.10. Residues marked with the asterisks correspo1d to residues or nucleotides identical in all sequences. 





M_tuberculosis      MFERFTDRARRVVVLAQEEARMLNHNYIGTEHILLGLIHEGEGVAAKSLE 50 
M_bovis             MFERFTDRARRVVVLAQEEARMLNHNYIGTEHILLGLIHEGEGVAAKSLE 50 
M_smegmatis         MFERFTDRARRVVVLAQEEARMLNHNYIGTEHILLGLIHEGEGVAAKSLE 50 
                    ************************************************** 
 
M_tuberculosis      SLGISLEGVRSQVEEIIGQGQQAPSGHIPFTPRAKKVLELSLREALQLGH 100 
M_bovis             SLGISLEGVRSQVEEIIGQGQQAPSGHIPFTPRAKKVLELSLREALQLGH 100 
M_smegmatis         SLGISLEGVRSQVEEIIGQGQQAPSGHIPFTPRAKKVLELSLREALQLGH 100 
                    ************************************************** 
 
M_tuberculosis      NYIGTEHILLGLIREGEGVAAQVLVKLGAELTRVRQQVIQLLSGYQGKEA 150 
M_bovis             NYIGTEHILLGLIREGEGVAAQVLVKLGAELTRVRQQVIQLLSGYQGKEA 150 
M_smegmatis         NYIGTEHILLGLIREGEGVAAQVLVKLGAELTRVRQQVIQLLSGYQGKEA 150 
                    ************************************************** 
 
M_tuberculosis      AEAGTGGRGGESGSPSTSLVLDQFGRNLTAAAMEGKLDPVIGREKEIERV 200 
M_bovis             AEAGTGGRGGESGSPSTSLVLDQFGRNLTAAAMEGKLDPVIGREKEIERV 200 
M_smegmatis         AEAGTGGRGGESGNPSTSLVLDQFGRNLTAAAMEGKLDPVIGREKEIERV 200 
                    *************.************************************ 
 
M_tuberculosis      MQVLSRRTKNNPVLIGEPGVGKTAVVEGLAQAIVHGEVPETLKDKQLYTL 250 
M_bovis             MQVLSRRTKNNPVLIGEPGVGKTAVVEGLAQAIVHGEVPETLKDKQLYTL 250 
M_smegmatis         MQVLSRRTKNNPVLIGEPGVGKTAVVEGLAQAIVHGEVPETLKDKQLYTL 250 
                    ************************************************** 
 
M_tuberculosis      DLGSLVAGSRYRGDFEERLKKVLKEINTRGDIILFIDELHTLVGAGAAEG 300 
M_bovis             DLGSLVAGSRYRGDFEERLKKVLKEINTRGDIILFIDELHTLVGAGAAEG 300 
M_smegmatis         DLGSLVAGSRYRGDFEERLKKVLKEINTRGDIILFIDELHTLVGAGAAEG 300 
                    ************************************************** 
 
M_tuberculosis      AIDAASILKPKLARGELQTIGATTLDEYRKYIEKDAALERRFQPVQVGEP 350 
M_bovis             AIDAASILKPKLARGELQTIGATTLDEYRKYIEKDAALERRFQPVQVGEP 350 
M_smegmatis         AIDAASILKPKLARGELQTIGATTLDEYRKYIEKDAALERRFQPVQVGEP 350 
                    ************************************************** 
 
M_tuberculosis      TVEHTIEILKGLRDRYEAHHRVSITDAAMVAAATLADRYINDRFLPDKAI 400 
M_bovis             TVEHTIEILKGLRDRYEAHHRVSITDAAMVAAATLADRYINDRFLPDKAI 400 
M_smegmatis         TVEHTIEILKGLRDRYEAHHRVSITDSAMVAAATLADRYINDRFLPDKAI 400 
                    **************************:*********************** 
 
M_tuberculosis      DLIDEAGARMRIRRMTAPPDLREFDEKIAEARREKESAIDAQDFEKAASL 450 
M_bovis             DLIDEAGARMRIRRMTAPPDLREFDEKIAEARREKESAIDAQDFEKAASL 450 
M_smegmatis         DLIDEAGARMRIRRMTAPPDLREFDEKIADARREKESAIDAQDFEKAAAL 450 
                    *****************************:******************:* 
 
M_tuberculosis      RDREKTLVAQRAEREKQWRSGDLDVVAEVDDEQIAEVLGNWTGIPVFKLT 500 
M_bovis             RDREKTLVAQRAEREKQWRSGDLDVVAEVDDEQIAEVLGNWTGIPVFKLT 500 
M_smegmatis         RDKEKQLVAQRAEREKQWRSGDLDVVAEVDDEQIAEVLGNWTGIPVFKLT 500 
                    **:** ******************************************** 
 
M_tuberculosis      EAETTRLLRMEEELHKRIIGQEDAVKAVSKAIRRTRAGLKDPKRPSGSFI 550 
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M_bovis             EAETTRLLRMEEELHKRIIGQEDAVKAVSKAIRRTRAGLKDPKRPSGSFI 550 
M_smegmatis         EEETTRLLRMEEELHKRIIGQEDAVKAVSKAIRRTRAGLKDPKRPSGSFI 550 
                    * ************************************************ 
 
M_tuberculosis      FAGPSGVGKTELSKALANFLFGDDDALIQIDMGEFHDRFTASRLFGAPPG 600 
M_bovis             FAGPSGVGKTELSKALANFLFGDDDALIQIDMGEFHDRFTASRLFGAPPG 600 
M_smegmatis         FAGPSGVGKTELSKALANFLFGDDDALIQIDMGEFHDRFTASRLFGAPPG 600 
                    ************************************************** 
 
M_tuberculosis      YVGYEEGGQLTEKVRRKPFSVVLFDEIEKAHQEIYNSLLQVLEDGRLTDG 650 
M_bovis             YVGYEEGGQLTEKVRRKPFSVVLFDEIEKAHQEIYNSLLQVLEDGRLTDG 650 
M_smegmatis         YVGYEEGGQLTEKVRRKPFSVVLFDEIEKAHQEIYNSLLQVLEDGRLTDG 650 
                    ************************************************** 
 
 
M_tuberculosis      QGRTVDFKNTVLIFTSNLGTSDISKPVGLGFSKGGGENDYERMKQKVNDE 700 
M_bovis             QGRTVDFKNTVLIFTSNLGTSDISKPVGLGFSKGGGENDYERMKQKVNDE 700 
M_smegmatis         QGRTVDFKNTVLIFTSNLGTSDISKAVGLGFSQGGSENNYERMKQKVHDE 700 
                    *************************.******:**.**:********:** 
 
M_tuberculosis      LKKHFRPEFLNRIDDIIVFHQLTREEIIRMVDLMISRVAGQLKSKDMALV 750 
M_bovis             LKKHFRPEFLNRIDDIIVFHQLTREEIIRMVDLMISRVAGQLKSKDMALV 750 
M_smegmatis         LKKHFRPEFLNRIDDIIVFHQLTQDEIIQMVDLMIGRVSNQLKTKDMALE 750 
                    ***********************::***:******.**:.***:*****  
 
M_tuberculosis      LTDAAKALLAKRGFDPVLGARPLRRTIQREIEDQLSEKILFEEVGPGQVV 800 
M_bovis             LTDAAKALLAKRGFDPVLGARPLRRTIQREIEDQLSEKILFEEVGPGQVV 800 
M_smegmatis         LSDKAKALLAKRGFDPVLGARPLRRTIQREIEDQLSEKILFEEIGPGQLV 800 
                    *:* ***************************************:****:* 
 
M_tuberculosis      TVDVDNWDGEGPGEDAVFTFTG--TRKPPAEPDLAKAGAHSAGGPEPAAR 848 
M_bovis             TVDVDNWDGEGPGEDAVFTFTG--TRKPPAEPDLAKAGAHSAGGPEPAAR 848 
M_smegmatis         TVDVEGWDGEGQGEDAKFTFSGGPKRAETAEPDLAGAG--AAGAPTAGTE 848 




SeqA Name                     Len(aa)  SeqB Name                     Len(aa)  Score 
=================================================================================== 
     M_tuberculosis_Rv3596c   848           M_bovis_Mb3627c          848      100   
     M_tuberculosis_Rv3596c   848           M_smegmatis_6091         848      94    
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Supplementary Data 2 
Sequence alignment of ClpP1 homologues corresponding to the Tuberculist entry for M. tuberculosis 
(Rv2461c), and the TIGR entry for M. smegmatis (4673 MC2). Residues marked with the asterisks 
correspo1d to residues or nucleotides identical in all sequences. ":" means that conserved substitutions have 
been observed. "." means that semi-conserved substitutions are observed. 
 
 
M_tuberculosis    MSQ---------VTDMRSNSQGLSLTDSVYERLLSERIIFLGSEVNDEIA 41 
M_smegmatis   MYQDVVESRYPVVTDMRGTGQGLNLVDSVYERLLAERIIFLGSQVDDDIA 50 
                     * *         *****...***.*.********:********:*:*:** 
 
M_tuberculosis   NRLCAQILLLAAEDASKDISLYINSPGGSISAGMAIYDTMVLAPCDIATY 91 
M_smegmatis          NRLCAQILLLSAEDPTKDIHLYINSPGGSISAGMAIYDTMVLAPCDIATY 100 
                     **********:***.:*** ****************************** 
 
M_tuberculosis   AMGMAASMGEFLLAAGTKGKRYALPHARILMHQPLGGVTGSAADIAIQAE 141 
M_smegmatis          AMGMAASMGEFLLAAGTKGKRYALPHARILMHQPLGGVTGSAADIAIQAE 150 
                     ************************************************** 
 
M_tuberculosis       QFAVIKKEMFRLNAEFTGQPIERIEADSDRDRWFTAAEALEYGFVDHIIT 191 
M_smegmati           QFAVIKKEMFRLNAEFTGQPIERIEADSDRDRWFTAQEALEYGFVDHIIT 200 
                     ************************************ ************* 
 
M_tuberculosis       RAHVNGEAQ------ 200 
M_smegmatis          SASVNGEGPGAGLDK 215 




SeqA Name                     Len(aa)  SeqB Name                     Len(aa)  Score 
=================================================================================== 
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Supplementary Data 3 
Sequence alignment of ClpP2 homologues corresponding to the Tuberculist entry for M. tuberculosis 
(Rv2460c), and the TIGR entry for M. smegmatis (4672 MC2). Residues marked with the asterisks 
correspond to residues or nucleotides identical in all sequences. ":" means that conserved substitutions have 
been observed. "." means that semi-conserved substitutions are observed. 
 
 
M_tuberculosis     MN----SQNSQIQPQARYILPSFIEHSSFGVKESNPYNKLFEERIIFLGV 46 
M_smegmatis MSNIHPSLDARLQPQARYILPSFIEHSSFGVKESNPYNKLFEERIIFLGV 50 
                   *.    * ::::************************************** 
 
M_tuberculosis     QVDDASANDIMAQLLVLESLDPDRDITMYINSPGGGFTSLMAIYDTMQYV 96 
M_smegmatis QVDDASANDIMAQLLVLESLDPDRDITMYINSPGGSFTSLMAIYDTMQYV 100 
                   ***********************************.************** 
 
M_tuberculosis  RADIQTVCLGQAASAAAVLLAAGTPGKRMALPNARVLIHQPSLSGVIQGQ 146 
M_smegmatis  RADIQTVCLGQAASAAAVLLAAGTPGKRLALPNARVLIHQPALSGVIQGQ 150 
                   ****************************:************:******** 
 
M_tuberculosis     FSDLEIQAAEIERMRTLMETTLARHTGKDAGVIRKDTDRDKILTAEEAKD 196 
M_smegmatis FSDLEIQAAEIERMRTLMETTLARHTGKDPAQIRKDTDRDKILTAEEAKE 200 
                   *****************************.. *****************: 
 
M_tuberculosis     YGIIDTVLEYRKLSAQTA 214 
M_smegmatis YGIIDTVLQYRKLSAQTS 218 
                   ********:********: 
 
 
SeqA Name                     Len(aa)  SeqB Name                     Len(aa)  Score 
=================================================================================== 
     M_tuberculosis_Rv2460c   214           M_smegmatis_MSMEG_4672   218      92    
=================================================================================== 
 
 
 
  
 
 
 
